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TRANSCRIPTION FACTOR REGULATION OF AMYLOID-BETA PATHWAY 
GENES BY SP1-MODULATING COMPOUNDS: A NOVEL APPROACH IN 
ALZHEIMER’S DISEASE 
Alzheimer's disease (AD) is a neurodegenerative disorder characterized 
by the presence of neuritic plaques consisting of extracellular amyloid-beta (Aβ) 
and neurofibrillary tangles comprised of hyperphosphorylated microtubule 
associated tau. Aβ is produced following the cleavage of amyloid precursor 
protein (APP) by the enzyme BACE1.  Transcription factors (TFs) are proteins 
involved in the regulation of gene transcription.  Expression levels of some TFs 
are perturbed in AD.  SP1 binding sites on both the APP and BACE1 promoters 
implicate its potential role in AD. Aβ peptide itself mediates activation of cyclin-
dependent kinase 5 (CDK5), an enzyme which phosphorylates the FOXO 
(Forkhead Box) TFs.  In order to study mechanisms of TF regulation of Aβ 
production in human models, neuronally differentiated cells as well as a primary 
human neurosphere culture were used to test the effects of TF-modulating 
compounds.  Our hypothesis is that by targeting relevant TFs via 
pharmacological inhibitors in human cells, BACE1 activity or APP expression will 
decrease and Aβ production will be reduced as a result.   
To test the involvement of TFs in the regulation of APP, we treated several 
mammalian cells lines and post-mitotic human neuronal cells with roscovitine, 
mithramycin A (MTM), MTM analogs (MTM-SDK, MTM-SK), and tolfenamic acid 
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(TA).  MTM and TA treatment of neurons differentially activated several TFs 
implicated in AD.  Treatment of differentiated neurospheres with MTM led to a 
significant decrease in APP and SP1 expression along with Aβ40 levels. 
Epigenetic mechanisms involve alteration of the binding affinity between DNA 
and transcription factors.  We predict that modulation of these TFs may be 
influenced by epigenetic modifications.  To test the effects of drugs on epigenetic 
markers, histone deacetylase (HDAC) and DNA methyltransferase (DNMT) 
activity was measured. MTM-SDK significantly decreased DNMT activity in 
differentiated neuroblastoma cells, this may enhance or decrease the ability of 
SP1 to bind to target DNA and affect transcription of BACE1 or APP.   
Targeting TF activity is a novel means to manipulate the amyloid pathway. 
Compounds modifying TF binding to sites on the BACE1 or APP promoters may 
provide a means to limit the production of amyloid-beta and slow the symptoms 
of AD. 
Debomoy K. Lahiri, Ph.D., Chair 
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I. Introduction 
Alzheimer’s disease (AD) is a major cause of death in the United States.  
The ways by which BACE1 is regulated likely plays a significant role in the way 
levels of amyloid-beta (Aβ) in the brain are controlled and therefore the 
symptoms of AD. BACE1 activity could play a critical role in the development of 
AD and may be an excellent drug target. Currently available BACE1 inhibiting 
drugs have been unsuccessful due to their many off-target effects. Widely used 
neuroscience models for AD study include cells derived from rodent or malignant 
sources.  We aim to focus on not simply globally blocking activity of BACE1, but 
on controlling how the expression of BACE1 and APP is regulated by 
transcription factors in dividing and non-dividing cells, including a novel primary 
human brain model, differentiated neurosphere culture.  Although it is known that 
SP1 is essential in the regulation of BACE1, the precise mechanism is not clear.  
It is imperative that the molecular mechanism related to transcription factor-
modulated reduction of amyloid pathway genes be understood in order to 
manipulate these effects on Aβ production.  Aβ peptide itself mediates activation 
of cyclin-dependent kinase 5 (CDK5), which phosphorylates the FOXO 
transcriptions factors.  We believe that SP1 and CDK5 dysregulation are key 
players in the production of Aβ.  Our hypothesis is that by targeting relevant 
transcription factors via both gene silencing and pharmacological inhibitors in 
human cells, BACE1 activity or APP expression will decrease and Aβ production 
will be reduced as a result.  The rationale for these studies is that this work will 
provide evidence for transcription factors as possible mechanistic targets for AD 
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study while also providing evidence for the value of a new cell culture model for 
the study of neurodegenerative diseases as a whole. 
A. Alzheimer’s disease & the amyloid hypothesis 
Alzheimer’s disease (AD) is the most common form of dementia in the 
elderly population of the United States [1]. AD is a progressive, 
neurodegenerative disorder characterized by loss of cognition and memory, 
personality changes, decline in physical capacity, and eventually leads to loss of 
life [2].  More Americans are surviving into their 80s and 90s, which has led to an 
increased interest among scientists to investigate diseases seen in the elderly as 
well as elucidating better treatments and potential cures. The segment of the 
American population over 65 is expected to grow drastically with the “baby 
boomer generation” having entered this stage in 2011.  Longer life expectancies 
and the aging baby boomers will dramatically increase the number of individuals 
at the highest risk of developing AD by 13 million people [3].  AD is currently the 
6th-leading cause of death in the United States [4].  It is difficult to accurately 
determine the number of deaths that are caused by AD because of the way the 
cause of death may have been recorded.  There is still a “blurred distinction 
between death with dementia and death from dementia [5].”  It is likely that AD is 
a contributing factor in the deaths of more patients than is actually reported by 
the Center for Disease Control.  Many patients with AD die from the disease itself 
or from conditions which AD caused, such as pneumonia.  Deaths attributed to 
AD increased 68% between 2000 and 2010, which is more than those attributed 
to heart disease [6].  The progression of AD can be quite variable among 
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patients.  Some patients over 65 survive four to eight years after diagnosis, while 
others may live up to 20 years with AD [7-10].  This is consistent with the slow, 
latent nature of this disease.  This insidious characteristic of AD is particularly the 
cause of the public health burden of the disease.  Most of the time patients spend 
in the severe stages of the disease require round-the-clock care, often in a 
nursing home or by unpaid caregivers [11].  The death rates for AD increase 
dramatically with age, which reflects the lack of effective treatments or a cure for 
this devastating illness. 
AD pathology is believed to result from the multiple factors including 
genes, the environment, as well as epigenetic mechanisms. The major 
pathological hallmarks of AD are extracellular amyloid plaques made up of 
fibrillar amyloid-β (Aβ) peptide and intracellular neurofibrillary tangles made up of 
hyperphosphorylated tau [12].  Synaptic loss is also a key pathological finding 
that correlates with the cognitive impairment seen in AD [13].  Importantly, the 
dysregulation of the production of the 40-42 amino acid-long Aβ peptides have 
been identified as an underlying cause of the formation of senile plaques 
observed in the brains of AD patients. Histologically, these Aβ peptide plaques 
are most pronounced in the hippocampus and cerebral cortex of the brain which 
represent regions critical to AD pathology [14]. To date, the deposition of Aβ in 
senile plaques at autopsy represents an important diagnostic criterion for AD 
pathology.  This project is aimed to address the hypothesis that the production of 
Aβ and its precursor (APP) can be modeled and studied in vitro in terms of 
neurobiology, transcription factor activation, and pharmacological effects. 
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i. The genetic basis of Alzheimer’s disease 
 Early-onset AD (EOAD) develops before the age of 65 and late-onset AD 
(LOAD; sporadic AD) develops after 65 years [15].  EOAD is caused by dominant 
mutations in APP, PSEN1, and PSEN2.  Sporadic AD has a genetic component 
of up to 60%-80%, however progression, disease severity, and onset are highly 
influenced by environmental factors as well [16].  
ii. Amyloid plaque formation pathways 
The rate-limiting step in the production of Aβ is the processing of amyloid- 
β precursor protein (APP) by a β-secretase, specifically β-site APP-cleaving 
enzyme (BACE1). Understanding the regulatory processes that modulate APP 
expression due to its direct role in the production of the precursor Aβ peptide is a 
key aim in proving the amyloid hypothesis.  However, these regulatory 
mechanisms that affect APP production still remain unclear. According to the 
“amyloid hypothesis,” AD is the result of the misregulation of the production or 
turnover of Aβ [17, 18].  There are mutations that may change how APP is 
cleaved to produce Aβ [19].  A key finding supporting the hypothesis is that most 
cases of EOAD are due to an increased ratio of the more toxic Aβ42 than Aβ40 
peptide [19, 20].  There is increased Aβ42 production when there are autosomal 
dominant mutations in the genes for APP, presenilin 1 (PSEN1), and presenilin 2 
(PSEN2) in EOFAD [21].  Furthermore, the late-onset AD risk factor, APOE-ε4, 
influences both Aβ clearance and its cerebral oligomerization [22].  In addition, 
individuals with Down’s syndrome with an increased dosage of the APP gene 
located on chromosome 21 overproduce Aβ42 and develop EOFAD [23].  
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Extracellular Aβ42 is known to be toxic to synapses and neurites by reducing 
synaptic plasticity and altering synaptic function in AD [24-26].   
iii. BACE1 dysregulation in Alzheimer’s disease 
One of the initial steps in the production of Aβ is the processing of APP by 
the aspartic protease BACE1.  APP is a type I membrane protein that is 
processed by three proteases (α-, β-, and γ-secretase) in two distinct pathways 
that are both part of normal processing: the amyloidogenic and the non-
amyloidogenic pathway.  Cleavage of APP by BACE1 at the N-terminus of the 
Aβ-domain yields secreted sAPPβ and a C-terminal fragment of APP (C99).  C99 
then is further processed by γ-secretase which leads to Aβ peptide secretion and 
generation of the C-terminal fragment (CTF) of APP [27].  This is the 
amyloidogenic pathway and the focus of this work (Figure 1).  .  Most γ-secretase 
cleavage occurs after residue 40, resulting in Aβ40 peptide.  Less commonly, 
however, cleavage occurs after residue 42.  This Aβ42 peptide is more 
hydrophobic and has a higher tendency to aggregate than Aβ40, which makes it 
the key component of amyloid plaques [28].  
Mice lacking BACE1 or γ-secretase do not produce Aβ or have cognitive 
deficits, making both secretases attractive drug targets [29-31].  Although BACE1 
is expressed ubiquitously, there are higher expression levels detected in neurons 
that have increased BACE1 activity [32].  BACE1 exhibits tissue-specific 
expression with the highest levels in the pancreas, then brain [33].  Brain BACE1 
expression is most profound in the hippocampus, a region known to have high 
expression of APP and Aβ.  Interestingly, BACE1 mRNA and protein levels can 
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also be detected in brain areas which lack APP and almost never produce Aβ 
[34, 35].  This may indicate other functions of BACE1 in other parts of the brain.  
BACE1 also has other transmembrane protein substrates besides APP including 
low-density lipoprotein receptor-related protein (LRP), β-amyloid precursor-like 
protein-1 (APLP1), β-amyloid precursor-like protein 2 (APLP2), the voltage-gated 
sodium channel β2 subunit (Navβ2), STGGal I, P-selectin glycoprotein ligand-1 
(PSGL-1), neuregulin-1(NRG1) and neuregulin-3 (NRG3) [36-44].  
Understanding these substrates and their functions is critical for understanding 
potential toxicity that could arise from inhibiting BACE1.  BACE1 mRNA and 
protein levels remain stable in human brain during aging, but BACE1 enzymatic 
activity is increased [45].  BACE1 protein levels and activity are both elevated in 
AD brain [46-48].  This increased BACE1 activity in AD brain correlates with 
reduced α-secretase activity [49].  BACE1 also is responsible for maintaining the 
balance of astrogenesis and neurogenesis in the hippocampus [50]. 
In rodents, the deletion of BACE1 prevents the production of Aβ and 
reduces AD-related symptoms [31]. However, the changes seen in BACE1 null 
mice are associated with subtle and transient defects that are actually restored 
later on in development [51].  These findings suggest that these behavioral 
effects are mostly significant during development, but not during mature stages 
of life [52]. Therefore, in addition to a pathological endpoint of AD, BACE1 
regulation likely represents an attractive drug target for treatment of AD 
pathogenesis. BACE1 is chiefly an attractive drug target because it is the rate-
limiting enzyme for Aβ production in cells [32].  There is also genetic evidence for 
7 
the role BACE1 plays in AD.  The Swedish double mutation responsible for a 
familial form of AD is located very close to the BACE1 cleavage site [28].  BACE1 
also cleaves this Swedish mutant APP 10- to 100-fold more efficiently than wild-
type APP [53, 54].  The 5’ UTR and the promoter region of BACE1 contain many 
transcription factor binding sites, such as nuclear factor (NF)-κB, signal 
transducer and activator of transcription (STAT1), and specificity protein 1 (SP1) 
[55, 56].  These regulatory elements and sites for regulation by transcription 
factors allow for further examination into how the BACE1 promoter specifically is 
involved in AD pathogenesis.  The BACE1 gene is located on chromosome 
11q.23.3.  It contains 9 exons and eight introns from a 30.6 kb region [57].  A 4.1 
kb promoter sequence (rising crosshatch) and a 5’ UTR (horizontal bars) are also 
present (Figure 2).  BACE1 expression is high in neuronal cells and has been 
well correlated with Aβ production.  Development of techniques to better 
understand the complex regulatory unit of the BACE1 gene and inhibit BACE1 
activity could be essential in reducing levels of Aβ and slowing AD pathogenesis. 
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Figure 1. Amyloid-beta production in AD.  The amyloid precursor protein 
(APP) is a transmembrane protein of 695, 751, or 770 amino acids depending 
on alternative splicing.  The most understood post-translational modification of 
APP is proteolytic cleavage by secretases, and in the production of Aβ, these 
secretases are BACE1 and γ-secretase. BACE1 cleaves APP at the β-
secretase site.  Source: Bayon, B.L. in preparation. 
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Figure 2.  Scale Schematic of BACE1 Genomic Sequence. Located on 
chromosome 11q23.  Indicating a 4.1 kb promoter sequence (rising cross-
hatch), a 5’-UTR (horizontal bars), nine exons (vertical lines), eight introns 
(horizontal line), and a 3’-UTR/terminator region of up to 4 kb (falling cross-
hatch). Lahiri et. al. 2006. J. Mol. Neurosci. 29; 65-80. Lahiri et. al. 2006. Curr. 
Alzheimer Res. 3(5): 475-483. 
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iv. APP dysregulation in Alzheimer’s disease  
Since its identification in 1987 by independent laboratories, many APP 
mutations have been identified that are associated with familial AD [58]. For 
instance, duplication or triplication of APP gene (seen in trisomy 21) leads to 
early-onset AD. Additionally, APP-deficient mice do not show notable changes 
other than decreased body mass, increased weakness of the extremities with 
increasing age, and gliosis of the brain [59].   
v. CDK5 dysregulation in Alzheimer’s disease 
Aβ peptide itself mediates activation of cyclin-dependent kinase 5 (CDK5) 
which is activated and localized to the cell membrane under physiological 
conditions [60]. CDK5 has been implicated in brain development, neuronal 
survival, learning and memory formation [61].  It is known that CDK5 is 
dysregulated in AD [62].  Aβ may over-activate CDK5, which can result in 
reactivation of the cell cycle and apoptosis in post-mitotic neurons [60].  CDK5 
activity can also result in phosphorylation of the tau protein [63].  The forkhead 
transcription factors (FOXO) have been implicated in many cellular processes.  It 
has been demonstrated that FOXO1 phosphorylation is lost in CDK5-deficient 
post-mitotic neurons [64].  CDK5 directly phosphorylates FOXO3 in the brain, 
leading to increased nuclear translocation of FOXO3 [65].  Activated FOXO3 
increases Aβ42 levels, which shows a relationship between phosphorylation of 
FOXO3 by CDK5 and AD [65]. This activation of the FOXO TFs Aβ could be 
targeted to treat AD.   
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B. Treatment of Alzheimer’s disease 
i. Current available treatments of Alzheimer’s disease 
There are three major therapeutic targets in the amyloid pathway to 
manipulate Aβ production: reduction of APP production, BACE1 inhibition, and γ-
secretase inhibition.  However, most of the treatments currently available for AD 
mostly aim to treat the late-stage symptoms of the disease.  There are no 
therapies which prevent or will delay the age of onset of AD [66].  Of all 
treatments yet developed for AD, none significantly change the course of the 
disease.  No drugs are available which target the APP processing pathway and 
Aβ production [28].  Many therapies are based on the idea that the cholinergic 
neurons undergo substantial progressive degeneration in AD [67, 68].  The 
development of cholinesterase inhibitors has been the focus of many 
pharmaceutical companies and in fact some have been approved by the US 
Food and Drug Administration (FDA) including donepezil, rivastigmine, and 
galantamine [69].  These therapies however are associated with small 
improvements in the symptoms associated with this devastating disease.  This 
has led to the need for alternative strategies for potential treatments.  An 
example of a new strategy is the targeting of microRNA (miRNA) to modulate 
AD-related gene expression [70].  It has been shown that miR-101 reduces APP 
levels in human cells [70].  Drug delivery is a key hurdle as there is not yet a 
delivery system that could get miRNAs to the cell population of interest.  Strides 
are being made by adding specific chemical modifications such as conjugation of 
lipid moieties to miRNA molecules to target the liver [71], but not yet to the brain.   
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Drug development failures include the non-steroidal anti-inflammatory 
agent (NSAID) tarenflurbil, and acetylcholinesterase inhibitors metrifonate and 
phenserine [72].  Semagacestat, a γ-secretase inhibitor, had to be pulled during 
Phase III trials due to side effects as well [73].  Another γ-secretase inhibitor, 
Avagacestat, made it to Phase II trials before being terminated due to clinical 
worsening [74].  From these studies, it seems focusing on a γ-secretase 
inhibition is unlikely to result in a viable drug treatment for AD.  Recently, the 
failure of Eli Lilly’s β-site APP-cleaving enzyme (BACE1) targeting drug 
LY2886721 made national headlines for its off-target effects on liver function [75]. 
However, it is not clear whether this toxicity was directly caused by BACE1 
inhibition [75].  Most recently, the November 2016 failure of solanezumab in 
phase 3 trials, cast further doubt on the amyloid hypothesis.  This drug, a 
monoclonal antibody, was designed to promote clearance of Aβ [76] and slow the 
progression of the disease [77].  There is a need to identify new drug targets in 
the preclinical setting, which may require reevaluation of current treatment 
agents or development of new model systems. 
ii. Treatment modalities under development in Alzheimer’s disease 
Emerging therapies include Aβ removal by immunization or intravenous 
immunoglobulins (IVIg), decreasing Aβ production, blocking Aβ signaling, and 
blocking tau-mediated toxicity [69].  Transcription factors themselves can be 
difficult drug targets as they can be involved in the regulation of several genes.  
However, modulating a transcription factor such as SP1 with tissue-specific 
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expression in the brain could produce a moderate decrease in BACE1 activity 
that could benefit AD patients in combination with other therapies. 
C. Transcription factors as druggable targets 
Transcription factors (TFs) as so-called “druggable” targets has been long 
debated.  The idea that a drug may regulate several genes by changing their 
activity may lead to many unwanted side effects.  TFs bind to specific sequences 
present within promoters, enhancers, and other regulatory regions of DNA, which 
is negatively charged. This means that TFs tend to be very positively charged 
and compounds targeting them would need to be negatively charged. Charged 
molecules do not easily cross cellular membranes, which makes them less than 
ideal for clinical practice.  There are, however, several advantages of targeting 
transcription factors in lieu of more conventional drug targets.  Specificity protein 
1 (SP1) is a transcription factor (TF) expressed in brain and involved in neuronal 
survival that may be dysregulated in Alzheimer’s disease (AD).  We aim to 
propose the continued study of SP1 as a transcription factor to target in AD.  
SP1, SP1-modulating drugs, their structures, and their effect of genes of the 
amyloid pathway are discussed in the following sections.   
i. Role of SP1 in Alzheimer’s disease 
The BACE1 promoter contains a number of transcription factor binding 
sites [55].  SP1 is a human transcription factor that binds to G-C rich motifs and 
can act as a repressor or as an activator.  SP1 regulates the transcription of a 
number of genes involved in a number of processes.  To better understand the 
mechanism of BACE1 gene expression and the relationship to SP1, Christensen 
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et. al. examined several cis-acting elements in the 5’ flanking region [78].  They 
demonstrated via transcriptional activation and gel shift assays that the BACE1 
promoter contains a functional SP1 response element.  They were also able to 
show that overexpression of Sp1 potentiates BACE1 expression and therefore 
generation of Aβ (Figure 3).  The BACE1 gene promoter was cloned and the 
transcription start site was mapped using a 5’ genome walking strategy and a 
primer extension assay.  Sequence analysis showed that the BACE1 gene had a 
complex transcriptional unit with a possible SP1 site.  This region, when deleted, 
showed marked BACE1 gene promoter activity.  Gel shift assays were performed 
to confirm whether or not this region was an SP1 site or not.  The gel shift assay 
showed the presence of an SP1 binding element at bp-911.  Deletion of this 
binding element from the BACE1 gene promoter resulted in a significant 
decrease in luciferase activity in a human embryonic kidney cell line (HEK293T).  
They performed experiments in a rat pheochromocytoma cell line (PC12), and 
deletion of the SP1 binding site again reduced the promoter activity as was seen 
in HEK293T.  The SP1-binding inhibitor mithramycin A (MTM) was used to treat 
cells since it has been shown to inhibit SP1 binding to DNA.  Treatment with 
MTM for 48 hours resulted in a significant reduction in BACE1 promoter activity 
in both a dose and time dependent manner (Figure 3).  They were also able to 
show that SP1 plays a critical role in the transcriptional regulation of the BACE1 
gene in humans by using SP1-/- ES cells (from SP1-KO mice).  Activation of 
BACE1 promoter activity was markedly reduced compared to that of wild type.  
This observation also demonstrated that SP1 is required for the BACE1 gene to 
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be properly transcribed.  To discover whether this requirement has an effect on 
APP processing and Aβ production, levels of BACE1, APP C99 (the major 
BACE1 cleavage product) and Aβ were analyzed in stably APP695-transfected 
HEK293 cells.  This stable cell line was then transfected with SP1 cDNA and 
then cells were treated with MTM.  MTM drastically reduced the generation of 
APP, C99, and Aβ.  These results suggest that inhibition of SP1 by MTM down 
regulates BACE1 expression and that BACE1 is a downstream target of SP1.   
Basha et al. were able to induce a robust and long-lasting increase in SP1 
expression in rats exposed to lead during the prenatal stage [79].  This protracted 
induction resulted in an increase in APP expression and Aβ production thus 
linking amyloidogenesis and SP1.  Studies outlined in this work look to expand 
on these findings by investigating mechanism of the effect SP1 inhibition of 
BACE1 expression has in human neurons.     
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Figure 3. Overexpression of SP1 in HEK293T cells increases BACE1 and 
Aβ; treatment with an SP1 inhibitor decreases BACE1 and Aβ. Christensen 
MA, Zhou W, Qing H, Lehman A, Philipsen S, Song W. 2004. Transcriptional 
regulation of bace1, the beta-amyloid precursor protein beta-secretase, by 
SP1. Molecular and cellular biology 24:865-874. 
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ii. The latent early-life regulation model: An epigenetic framework for 
transcription factor regulation of late-onset neurodegenerative 
disease 
The latent early-life associated regulation (LEARn) model provides specific 
mechanisms to predict targets for late-onset disorders such as AD [46].  This 
model is based on the environmental induction of dormant epigenetic changes 
[47].  LEARn explains idiopathic disorders on the basis of accumulation of ‘hits’ 
throughout life. Hits may be environmental, genetic or epigenetic [80]. After 
accumulating additional environmental insults, disease develops later in life.  
Proteins that are susceptible to this phenomenon can be called “LEARned [48]” 
This theory proposes that a first hit occurs early in life [47].  This could simply be 
an exposure to an environmental toxin, change in nutrition, or head trauma [49, 
50, 53, 54].  This exposure leads to stress than causes a change in regulatory 
sequences of the gene at some important, developmental stage of life.  This so-
called hit is maintained epigenetically (i.e. methylation or oxidation of DNA) 
during a latency period for what could be many years [46].  During this period of 
time, normal gene expression is observed and there are no phenotypic 
manifestations of the first hit.  Eventually, a second hit (i.e. exposure to metals, 
dietary factors) occurs and becomes an additional stressor.  This causes the 
accelerated loss of function of this gene expression and the threshold of disease 
and symptom development is crossed.  LEARn proposes a sort of intermediate 
step between genotype and phenotype. The environment induces this epigenetic 
modification of a gene to produce a “somatic epitype [54].” This somatic epitype 
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determines gene expression levels which correspond to the pathological state 
(Figure 4).  Therefore, the LEARn model operates through the regulatory region 
or promoter of a gene.  Basha et. al. demonstrated that rats exposed to lead (Pb) 
early in life showed a transient increase in APP expression, yet a delayed 
overexpression 20 months after exposure had ended [79].  This late increase in 
expression also correlated with an increase in SP1 activity.  They also observed 
that APP expression, SP1 activity, and Aβ levels did not respond to Pb exposure 
later on in life.  This suggests that these environmental influences that occur 
during development have a unique effect on amyloidogenesis later in life.  They 
profiled a number of transcription factors after developmental exposure to Pb 
including SP1 by performing a macroarray screen on postnatal day 5.  Postnatal 
day 5 is the day in rats that correlates with the highest APP levels.  SP1 levels 
were highly induced following Pb exposure.  Lifelong SP1 binding was then 
monitored.  SP1 DNA-binding increased dramatically 20 months after Pb 
exposure had ceased.  We propose that most AD cases would follow a LEARn 
etiology and specifically, that SP1 is a “LEARned” protein.  Although these 
studies are critical and quite informative in discovering the connection between 
APP, SP1, Pb, and Aβ levels, they are limited as they do not address these 
interactions in a human model.  Studies outlined in this work specifically address 
this limitation as some studies will be conducted in differentiated neurospheres 
derived from human fetal brain tissue.   
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Figure 4.  The latent early-life associated regulation model.  
(A) Genetic pathway for a ‘purely’ genetic disorder, such as Alzheimer’s 
disease (AD) due to familial dominant mutation. AD-associated genes’ DNA 
sequence variant determines the disease state. (B) Development of disease 
via LEARn pathway. A primary ‘hit’ between conception and a critical 
developmental time point leads to latent epigenetic changes. If followed by 
subsequent ‘hits’, accumulated risk factor effects will reach clinical disease 
state as in the sporadic AD. (C) LEARn pathway across generations: t-LEARn. 
Similar to LEARn progression except the original ‘hit’ has occurs in an earlier 
generation and is transmitted asymptomatically by epigenetic inheritance. (D) 
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Remediation pathway or ‘Averted’ LEARn. Given that many epigenetic marker 
states can be altered by environmental factors, including nutrition and drugs, 
the possibility exists that one or more of the effects of a given ‘hit’ may be 
reversed by these means. Should this occur, accumulated effects will not reach 
clinical disease [80].  
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iii. Transcription factor modulating compounds 
a. Mithramycin A 
Mithramycin A  (MTM) is a natural aureolic acid-type aromatic polykeditde 
antibiotic produced by various species of Streptomyces [81].  MTM binds GC-rich 
regions within the DNA minor groove and displaces SP1 family proteins from the 
binding sites of many genes [82].  MTM displaces SP1 from sites on the 
promoters of several oncogenes, which has made it an extensively studied 
chemotherapeutic agent for years [83].  By displacing SP1 from its binding sites 
on oncogene promoters, MTM induces apoptosis via down-regulation of myeloid 
cell leukemia-1 (Mcl-1) [84].  Sleiman et al. were able to show via promoter 
analysis and chromatin immunoprecipitations that MTM does not displace SP1 or 
SP3 from every promoter in neurons, illustrating that MTM is able to selectively 
displace SP1 at some sites and not others [83].  MTM diffuses rapidly into 
neuroblastoma cells to bind to DNA [85].  The affinity MTM has for GC-rich 
sequences and its ability to compete with SP1 for binding to BACE1 promoter 
DNA are two factors influencing its pharmacological potential in AD.  MTM is a 
tricyclic chromophore with a hydrophilic side chain at the 3-position [83].  Multiple 
acyl-CoA units proceed through type II polyketide synthase (PKS) mediated 
condensation to form demethylpremithramycinone and premithramycinone.  
Premithramycinone is glycosylated, then C-methylated to form premithramycin B.  
The fourth ring is cleaved, the 4’-keto group is decarboxylated and reduced 
catalyzed by oxygenase MtmOIV and ketoreductase MtmW [86].  MTM is FDA 
approved for treatment of testicular cancer and leukemia [83].  Other applications 
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for MTM use include Paget bone disease and hypercalcemia [87, 88].  MTM 
shows promise in the treatment of glioblastomas, inhibition of the Friend 
leukemia virus integration 1 (EWS-FLI1) transcription factor in pancreatic cancer, 
and in the inhibition of the multi-drug resistance efflux pump MDR1 [89-91].  
Because MTM inhibits SP1 interaction with binding sites of SV40 and c-myc 
promoters, it also has a potential role in AIDS therapy [92]   
A few studies have shown that MTM can enhance neuronal survival.  
Chatterjee et al. showed that MTM is able to suppress neuronal apoptosis as a 
result of DNA damage or oxidative stress while not affecting global protein 
synthesis [93].  MTM has been shown to improve behavior and increase survival 
of Huntington’s disease (HD) mice [94, 95]. Studies also suggest that MTM can 
protect against dopaminergic neurotoxicity in mice after the administration of 
methamphetamine [96].  The protective effects MTM has in neurons may derive 
from a reduction in SP1 binding promoters of typically associated with cancer 
[83].  There is a reduction in the expression of these select oncogenes that 
“covaries with a biological phenotype of neuroprotection in neurons” [83].  
Inhibition of Myc, c-Src, Erk, and Raf protects neurons [83, 97-101].  There may 
be a mechanistic connection between neurodegenerative and oncogenic 
pathways.  Mutations in APP can not only lead to AD, but also leukemia [102].  
The Cdc42/Rac and retinoblastoma p130 oncogenic pathways have also been 
shown to contribute to AD [103, 104].  If MTM is functioning in both oncogenic 
and neurodegenerative pathways, it will be interesting to elucidate the 
mechanistic pathway possibly related to aging.  These studies suggest the 
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potential for the use of MTM as a therapeutic agent in CNS diseases with 
neurodegeneration.  Use of MTM has been limited due to its side effects 
including gastrointestinal, bone marrow, hepatic, and renal toxicities [105-107].   
b. MTM-SDK and MTM-SK 
MTM analogs MTM-SDK and MTM-SK were created by genetic 
manipulation of the MTM biosynthetic pathway [108, 109]. MTM analogs have 
favorable characteristics such as enhanced potency and decreased toxicity to 
cells.  MTM-SDK (for Short side chain, DiKeto) differs from MTM in structure and 
length of the hydrophilic side chain [83].  It has been previously shown that the 3-
side chain is partially responsible for MTM interacting with the phosphate 
backbone of DNA [110, 111].  MTM-SDK has a shorter side chain at the 3-
position as compared to MTM.  MTM-SDK and MTM-SK (for Short side chain, 
Keto) have a greater ability to block SP1 binding to DNA than does MTM [85, 
112].  This leads to the idea that the 3-side chain is critical in the activity of MTM 
and therefore its analogs.  A genetically engineered S. argillaceus strain, M7W1, 
contains an inactivated mtmW gene.  The mtmW gene encodes MtmW, the last 
acting enzyme in the MTM biosynthetic pathway [113].  The inactivation of this 
gene produces the MTM analogs MTM-SDK and MTM-SK.  MTM-SDK and 
MTM-SK are formed from the spontaneous rearrangement of MTM-DK [114].  
Synthetic modifications allow for the introduction of different functions and 
properties of MTM analogs.  Both MTM-SDK and MTM-SK exhibit higher 
anticancer activity than does MTM [85, 115].  Both analogs are being used in 
studies looking to improve bioavailability and increase plasma retention time 
24 
[114].  MTM-SK has been shown to exhibit the same potency as MTM in 
neuroblastoma cells [85].   
c. Tolfenamic acid 
Tolfenamic acid (TA) is a non-steroid anti-inflammatory drug (NSAID) 
which inhibits cyclooxygenase (COX) activity and synthesis of prostaglandin 
[116].  TA has also been shown to attenuate the degradation of SP1 which 
reduces the transcription of both APP and BACE1 [117, 118].  Expression of 
BACE1 is reduced as well as Aβ production [119, 120].  TA has also been shown 
to rescue neuroblastoma cells from an increase in SP1, APP, and Aβ induced by 
lead exposure [118].  The exact mechanism by which TA promotes degradation 
of SP1 is unknown.  Intracellular neurofibrillary tau tangles are a hallmark in AD 
brain and in transgenic mice, and interestingly TA lowers both tau mRNA and 
protein [121].  TA has been implicated in the regulation of many tumor 
suppressive TFs such as CHOP and ATF3 [122].  Evidence suggests that TA 
blocks TNF-α- or LPS-induced NF-κB activation in human cells [123].  Caspases, 
survivin, c-Met, VEGF, c-PARP, and cyclin expression are all modulated by TA 
[124].  TA decreases the gene expression of CDK5, which is responsible for the 
phosphorylation of tau [125].  TA has been shown to interrupt the de novo 
synthesis of APP and to change downstream levels of Aβ in C57BL/6 mice and in 
hemizygous R1.40 transgenics [119, 120].  It is promising that TA reduces 
plaque pathology in AD mouse models along with improving memory [126].  
These many interactions indicate that TA can affect apoptotic, anti-inflammatory, 
as well as Aβ pathways.  This complex mechanism of action may allow TA to 
25 
partially mediate many effects, including the suppression of BACE1 promoter 
activity via SP1 degradation, while also interrupting the pathological tau tangle 
phosphorylation pathway leading to a promising use in AD studies. TA (brand 
name Clotam) has been used in Europe and Asia for the treatment of migraine 
headaches and rheumatoid arthritis for several decades [127, 128].  The safety 
profile and pharmacokinetics of TA in humans has already been well established 
with its long use for the treatment of migraine headaches in Europe.  Its 
interference with SP1 has not revealed worrying effects on adults taking this drug 
[129].  However, the side effects of TA are consistent with other NSAIDs.  
Gastrointestinal bleeding and ulcers can occur at high doses, but occurs less 
frequently that with ketoprofen, indomethacin, and naproxen [130].  Chronic 
administration of TA in mice did not result in changes in hemoglobin or 
hematocrit [124]. 
d. Roscovitine 
CDK5 has been implicated in AD.  Mice with increased cerebral CDK5 
activity were shown to have increased levels of BACE1 and Aβ [131, 132].  Also, 
CDK5 along with its activator proteins p25 and p35 have been shown to be 
dysregulated in post-mortem AD brain [133].  Forkhead box proteins are a 
transcriptional activator which triggers neuronal cell death upon oxidative stress 
(Brunet et al. 1999).  FOXO1 and FOXO3a are highly expressed in the human 
brain, specifically in areas susceptible to AD (Hoekman et al. 2006).  
Dysregulated CDK5 causes neurotoxic Aβ processing and cell death, by 
phosphorylating FOXO3a (Shi et al. 2016).  
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Roscovitine is a selective cyclin-dependent kinase (CDK) inhibitor with 
various anti-inflammatory, -proliferative, -apoptotic, and neuroprotective effects in 
different cell types [134].  It is being researched for the treatment of non-small 
cell lung cancer (NSCLC), leukemia, HIV infection, and cystic fibrosis [135].  
Roscovitine has been shown to interrupt activation of NF-κB and to reduce 
expression of TNF-α-induced proinflammatory gene [136].  It also downregulates 
Mcl-1 and decreases cyclin D1 expression [134, 137].  As a CDK5 inhibitor, 
treatment with roscovitine can influence phosphorylation of the FOXO proteins.  
CDK5 inhibition has been shown to stabilize FOXO1 leading to an increase in its 
transcriptional activity [138].   
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D. Research plan 
 In order to investigate the effect of TF-modulating drugs on other 
transcription factors and Aβ pathway genes, a well-characterized human cell 
culture model is needed.  Given the expense, unknown variables present, and 
differences in the development of AD-pathology of AD model animals, tissue 
culture has been chosen as the model for this work.  Tissue culture allows cells 
to provide information on cell response to transfection and drug treatment in a 
faster time frame than with model animals.  Although further removed from 
disease states than animal models, we choose human models which are more 
aligned with the species specific characteristics of AD.  Furthermore, our use of 
primary human neuronal (HFN) and differentiated neurospheres (dNSPc) allow a 
mixed culture with populations what recapitulate that of the brain.  These cells 
are a better approximation of the in vivo cell populations than can be available in 
cancer cell lines.  Fetal tissues will be used because they were obtainable in 
regular quantities and easy to dissociate, allowing for greater chances for data 
collection per shipment of tissue.  Prior to drug treatments and manipulations via 
siRNA, it was necessary to characterize the cultures and optimize culture 
conditions.  Human fetal neuron culture was previously described by our 
laboratory [139].  Characterization of both undifferentiated and differentiated 
neurosphere culture were done as part of this work in order to determine the 
nature of the cell population under particular cell culture conditions over time.   
 Cell lines were used in preliminary experiments to measure tolerance of 
cells to the drugs of interest, antibody characterization, and validation.  It is 
important to understand the differences in protein expression across cell types.  
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Human epithelial (HeLa), glial (U373), neuroblastoma (SK-N-SH, NBRA), and 
induced pluripotent stem cells (iPSCs) were all used for these purposes.  In 
addition, the rat pheochromocytoma cell line, PC12 was used to optimize plating 
conditions for the Incucyte Zoom.  This is due to the ease of detection of neurites 
in PC12 differentiated with neuronal growth factor (NGF).  It was presumed that 
in the primary cell cultures (HFN and NSPc), there would be more variation in 
protein expression.  Use of well-characterized, pre- and post-mitotic cell lines 
provide a detailed understanding of the effect of MTM, MTM-SDK, MTM-SK, TA, 
and roscovitine on protein expression.   
 Many proteins have been implicated in AD.  Of particular interest in this 
study is the aberrant expression of BACE1, APP, and SP1 (Figure 6).  Also of 
interest is CDK5 and its role in activation of TFs FOXO1 and FOXO3.  The 
proteins of interest in these cultures over time also include neuronal and glial 
markers NSE and GFAP, respectively.  Synaptic proteins synaptophysin and 
SNAP25 are both considered because they have been shown to be reduced in 
AD [140].  Of greater interest, however, is how SP1, FOXO1, FOXO3, and other 
transcription factors regulate AD-relevant genes.  Thus, understanding how these 
drugs, thought to be TF-modulators, potentially activate several other TFs that 
mediate the reduction of BACE1 activity, APP expression, and/or amyloid-beta 
production.  This was carried out by the transduction of both primary cells and 
cell lines with reporter genes driven by TF activation followed by the appropriate 
reporter assay.  These, along with predictive tools and literature searches, help 
to elucidate a possible mechanism for SP1 or other TF-modulation of Aβ pathway 
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genes.  It is expected that SP1 along with a few other TFs modulate BACE1 
activity, APP expression, and Aβ clearance/production in a manner that could be 
disease-modifying with the proper pharmacological intervention.   
II. Materials and Resources 
For a comprehensive list of reagents used in experiments, see Table 2. 
A. Tissue culture 
 Cells were maintained and treated according to cell line type.  HeLa, 
U373, and naïve SK-N-SH cells were cultured in MEM containing 10% fetal 
bovine serum (FBS) and 1X antibiotic.  PC12 were cultured in RPMI medium 
containing 10% heat-inactivated horse serum and 5% FBS.  Cells were seeded 
into tissue culture treated polystyrene multiwall plates (Corning).   
 MTM was obtained from Santa Cruz. Analogs MTM-SDK and MTM-SK 
were obtained from the laboratory of Rajiv Ratan of the Burke Medical Research 
Institute in Cornell University.  TA was obtained from Sigma.  All drugs were 
reconstituted in DMSO to make stock solutions that were diluted in media for 
treatments. 
B. Western immunoblotting 
Western immunoblotting was used in order to detect proteins of interest.   
i. BSA protein estimation and sample preparation 
Cells were lysed in RIPA buffer containing complete protease inhibitor 
cocktail.  Protein content of these samples was estimated using the Pierce BSA 
Protein Assay Kit (Thermo).  BSA was used to generate a standard curve to 
allow calculation of the protein content of each sample.  This estimation allowed 
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sample volume to be adjusted and for relatively equal loading of protein per lane.  
Loading volume in the gels were limiting, and in some cases, the maximum 
volume loaded was dependent on the least concentrated sample.  Samples were 
prepared in 4X Laemmli Sample Buffer (BIO-RAD) and heated to 95°C for 10 
minutes using a thermal cycler (BIO-RAD).   
ii. Electrophoresis conditions 
Samples were loaded onto SDS-PAGE gels and 200 V was applied for the 
time needed to allow the bromophenol blue tracking dye front to pass completely 
through the gel (generally 1 h).  The gels were then removed and transferred to 
membranes via wet or dry transfer methods. 
iii. Criterion XT Western blot system 
The Criterion XT Western Blot System (BIO-RAD) is a precast SDS-PAGE 
system.  In these experiments, the 12% polyacrylamide, 26-lane gels were used.  
Large numbers of samples were able to be resolved on the same gel (e.g. drug 
treatments with n ≥ 4 for each compound and dosage).   
iv. Mini Protean II Western blot system 
In experiments requiring a higher loading volume than the 26-lane gels 
allow, the Mimi Protean II System (BIO-RAD) was used.  Western blots produced 
by this system allow 10-15 samples, but at volumes up to 35 µL as compared to 
about 12 μL in the Criterion XT gels.   
v. Wet transfer system 
Gels were removed and placed in a tray of transfer buffer containing 20% 
methanol, and allowed to equilibrate for 10 min.  Proteins were then transferred 
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to a 0.22 µm pore size PDVF membrane (BIO-RAD).  Protein transfer was 
visualized using 0.1% (w/v) Ponceau S stain in 5% v/v acetic acid (Fisher).  
Excess stain not bound to protein was washed off with 5% acetic acid and the 
blot was electronically scanned using a desktop scanner.   
vi. iBlot gel transfer system 
The Invitrogen iBlot® 7-Minute Blotting System is comprised of the iBlot™ 
Gel Transfer Device and iBlot™ Gel Transfer Stacks.  An 8 min transfer protocol 
was used.  Gel was placed on the transfer membrane of the anode stack and air 
bubbles were removed with a roller.  One piece of water pre-soaked filter paper 
was placed on top of the gel.  The cathode stack was placed on the filter paper 
and air bubbles were again removed with a roller.  A disposable sponge was 
placed in the lid of the gel transfer device and the anode-filter paper-gel-cathode 
stack was placed on the blotting surface.  The lid of the device was closed and 
latched, then the 8 minute program was selected (20 V).  After transfer, the 
membrane was removed, quickly rinsed with methanol, then acetic acid before 
Ponceau S staining.   
vii. Antibody incubation conditions 
After Ponceau S stain was rinsed off with several washes of 1X Tris 
buffered saline (TBS; Thermo), primary antibodies were applied in a solution of 
casein blocker in TBS  at antibody-specific dilutions listed in Table 1.  Primary 
antibodies were applied overnight at 4°C.  The following day, blots were washed 
4 times for 5 minutes each in TBST before secondary antibody solution was 
added.  The appropriate host-specific HRP secondary antibody was also 
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prepared in casein blocker in TBS.  The blots were incubated in secondary 
antibody solution at room temperature for 1 h on a rocker.  After incubation, the 
blots were washed 6 times for 5 minutes each in TBST.  
viii. Detection  
Protein was detected using enhanced chemiluminenscence (ECL; 
Thermo) according to manufacturer’s instructions.  The detection reagents were 
applied to the blot for 2 min, then the blot was placed in a transparent plastic 
sheet protector and exposed to film (Thermo) for the required amount of time 
specific to each antibody.  Exposure times of between 30 sec to 3 min were 
required for most proteins depending on the relative abundance of the protein in 
a particular sample.   
ix. Antibodies 
Primary antibodies and source are listed in Table 1.  Horseradish 
peroxidase (HRP) conjugated secondary antibodies were obtained from Pierce 
(Rockford, IL; anti-mouse and anti-goat) or from Sigma.  For 
immunocytochemistry, secondary antibodies and avidin conjugates were all 
obtained from Jackson ImmunoResearch Laboratories (West Grove, PA).   
a. SP1, APP, and BACE1 levels in dividing cells vs. nondividing cells 
Antibodies were optimized for use in various cell types.  Decreasing 
concentrations of proteins from cell lysates of HeLa, SK-N-SH, differentiated 
neurospheres, and U373 were loaded onto a 10% polyacrylamide gel and 
separated by SDS-PAGE.  Protein was transferred to PVDF by iBlot gel transfer 
system and probed with SP1 antibody (Figure 5, 6).  Expression levels of SP1 
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are lower in glial and neuroblastoma cell lines then in human neurosphere cells 
and HeLa.  Specificity of the SP1 antibody was tested by SP1 siRNA transfection 
of HeLa cells (Figure 7b).  SP1 siRNA transfection significantly knocked down 
SP1 protein levels in HeLa as detected by Western blot.  
To optimize use of BACE1 antibody, 2 commercially available antibodies 
were tested which recognize different epitopes of BACE1 (Figure 9).  Human 
adult brain, human adult AD brain, human fetal brain (DIV0), U373, SK-N-SH 
cells differentiated with retinoic acid (NBRA), HeLa, and rat kidney were analyzed 
via Western blot for levels of BACE1 (Figure 9). BACE1 levels were detected in 
fetal brain by both abcam and R&D antibodies.  BACE1 is also easily detected in 
adult brain by the R&D antibody.  Probing with R&D BACE1 antibody, however, 
did not reveal bands in kidney, U373, NBRA, or HeLa cell lysates.  The abcam 
antibody was able to detect protein in adult brain, U373, NBRA, HeLa, and fetal 
brain, but not in kidney.  BACE1 abcam antibody was chosen for use in future 
experiments.  A cohort of human brain specimens from human cortex was 
obtained from the lab of Peter Nelson.  The cohort is comprised of 5 controls and 
15 AD specimens.  The AD specimens are further sub-grouped by exposure to 
AD therapeutics (Figure 10).  Brain specimens were analyzed for detection of 
BACE1 and housekeeping proteins.  To validate the authenticity of the APP 
antibody, an siRNA experiment was performed in U373 (Figure 11).   
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Table 1. Antibodies used in Western immunoblotting (WB), 
immunocytochemistry (ICC), and flow cytometry (FC) 
Antibody 
(Ab) Source Catalog  Host Use 
Ab 
Type 
Expected 
Size (kDa) Dilution 
Alzheimer 
Precursor 
Protein (APP) 
A4 
Millipore MAB348-100UL 
mous
e WB 1° 
110,120,13
0 1:3000 
BACE1 Vassar Lab  
mous
e WB 1° 75 1:500 
BACE1 abcam ab2077 rabbit WB 1°  70 1:500 
BACE1 R&D MAB931 mouse WB 1° 60-75 1:1000 
Biotin-SP-
conjugated 
AffiniPure 
Donkey Anti-
Mouse IgG 
Jackson-
Antibodie
s 
715065-
150 
donke
y 
ICC
, 
FC 
2°  1:1000 
CDK5 Cell Signaling 2506 rabbit WB 1° 30 1:1000 
Cy3-
conjugated 
Donkey Anti-
Goat 
Jackson-
Antibodie
s 
705-165-
147 
donke
y 
ICC
, 
FC 
2°   1:300 
Cy3-
conjugated 
Donkey Anti-
Rabbit 
Jackson-
Antibodie
s 
711-165-
152 
donke
y 
ICC
, 
FC 
2°   1:300 
Doublecortin Cell Signaling 4604 rabbit WB 2°  1:1000 
DTAF-
conjugated 
Streptavidin 
Jackson-
Antibodie
s 
016-010-
084  
ICC
, 
FC 
2°    
Foxo1 Cell Signaling 2880 Rabbit WB 1° 78-82 1:1000 
Foxo3a Cell Signaling 12829 Rabbit WB 1° 82-97 1:1000 
GAPDH Sigma G9545 rabbit WB 1° 36 1:10,000 
GFAP Sigma G9269 rabbit 
WB
, 
ICC
, 
FC 
1° 46 1:2000 
Goat anti-
Rabbit IgG 
Secondary 
Antibody, 
HRP 
conjugate 
Thermo 
Scientific 31460 goat 
ICC
, 
FC 
2°  1:3000 
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HRP Western 
Blot Anti-
Mouse IgG 
Rockland KCB002 goat WB 2°  1:200,000 
Nestin abcam ab22035 mouse 
WB
, 
ICC 
1° 176 1:3000 
NSE Abcam ab16873 rabbit 
WB
, 
ICC
, 
FC 
1° 47 1:1000 
Pan-Neuronal Millipore MAB2300 
mous
e 
ICC
, 
FC 
1°  1:1000 
PSD95 Neuromab 75-028 
mous
e WB 1° 95-110 1:1000 
SNAP25 Chemicon MAB331 
mous
e WB 1° 26-27 1:1000 
SP1 Millipore 07-645 rabbit WB 1° 95-105 1:500 
Synaptophysi
n 
Cell 
Signaling 5461 rabbit WB 1° 38 1:1000 
α-tubulin Sigma-Aldrich T9026 
mous
e WB 1° 50 1:50,000 
β-actin Sigma-Aldrich A5441 
mous
e WB 1° 42 1:50,000 
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Figure 5. Differential expression of SP1 in various cell types.  Decreasing 
concentrations of protein from HeLa, SK-N-SH, differentiated neurospheres 
(NSP), and U373 were loaded on a gel, transferred by iBlot to PVDF 
membrane, and probed with SP1 antibody.  Signal is faint in U373 even at 
higher concentrations of lysate loaded.  Expression levels of SP1 are 
noticeably lower in glial and neuroblastoma cell lines. 
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Figure 6. SP1 is differentially expressed in various CNS cell types. A) SP1 
levels as detected by Western immunoblotting.  Relative levels of SP1 in U373 
are lower than that of HeLa, SK-N-SH (NB), or undifferentiated neurospheres 
(NSP).  B) siRNA knockdown in various cell lines. Transfection of HeLa cells 
with SP1 siRNA confirms the authenticity of the SP1 band. 
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Figure 7. Schematic comparing two commercially available BACE1 
antibodies.  BACE1 from R&D and abcam recognize different epitopes of 
BACE1 protein.  R&D detects between amino acids 22 – 460 and the abcam 
485 – 501. Source: Bayon, B.L., in preparation. 
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Figure 8. Comparison of two commercially available BACE1 antibodies 
and expression in various cell types.  The abcam and R&D antibodies 
differentially detect BACE1 in adult brain, U373, NBRA, and HeLa.  R&D 
antibody detects BACE1 at 60 kDa, abcam at 70 kDa.  An siRNA experiment in 
U373 was used to confirm the authenticity of the BACE1 band seen with the 
BACE1 antibody from the Vassar lab in U373.  A band was detected at nearly 
75 kDa in all but the BACE1 siRNA transfected lysates.  The abcam and 
Vassar lab antibody was used in subsequent experiments.   
 
  
           Mock               SP1 siRNA     BACE1 siRNA      APP siRNA 
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Figure 9. BACE1 expression in human brain samples. Control (n=5) and 
AD (n=15) human brain tissue samples examined by Western immunoblotting 
after SDS-PAGE.  AD specimens further sub-grouped by exposure to AD 
therapeutics Aricept/Razidine, Exelon, Namenda, or no drug treatment.  Alpha-
tubulin, beta-actin, and GAPDH were used as loading controls.  BACE1 
(abcam) antibody detects protein at about 70 kDa in human adult brain.  No 
significant changes were detected among controls versus AD subjects. 
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Figure 10.  APP Expression in U373.  The authenticity of the APP antibody 
was confirmed by siRNA transfection of U373 cells.  siRNA transfected cells 
show complete knockdown of APP levels.   
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C. Immunocytochemistry (ICC) 
After treatment, cells were washed with PBS in 24-well plates and fixed in 
4% paraformaldehyde for 10 min.  Wells were then washed twice with PBS to 
remove traces of paraformaldehyde.  All PBS was removed, and then 0.25% 
Triton-X (Sigma) was added for 15 min to permeabilize the cell membranes.  
Wells were then washed 3 times with PBS to remove all traces of Triton-X.  
Nonspecific binding was then blocked using 10% horse serum in PBS for 30 min.  
Primary antibodies were applied at the antibody-specific dilutions as indicated in 
Table 1 in 1% horse serum overnight at 4°C.  The following day, wells were 
washed 3 times for 5 minutes with PBS.  Host-appropriate secondary antibodies 
were applied in 1% horse serum for 1 h and washed 3 times for 5 minutes with 
PBS.  Secondary antibodies were conjugated to fluorescein isothyocyanate 
(FITC), cyanine-3 (Cy-3), or biotin.  Biotinylated secondary antibodies were 
subsequently incubated with either Cy-3 or FITC conjugated streptavidin.  Biotin 
and FITC conjugates were used at 1:300 dilutions, while Cy-3 secondary 
conjugates were used at a 1:1500 dilution.  All secondary agents and streptavidin 
conjugates were from Jackson Immunoresearch.   
D. Amyloid-beta 40 ELISA 
ELISA kits were obtained from Invitrogen.  The kits contained microwell 
plates pre-coated with capture antibodies, and HRP-labeled detection antibodies 
were provided in the same kit.  Samples (50 µL) were added to the plate followed 
by detection antibody and allowed to incubate for 3 h at room temperature (RT).  
Wells were washed 4 times, then 100 µL of HRP anti-rabbit antibody was added 
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for an incubation time of 30 min at RT.  Wells were washed 5 times, then 100 µL 
of stabilized chromogen was added for 30 min at RT.  Lastly, 100 µL stop 
solution was added to wells and absorbance read at 450 nm.  
E. Human Brain Samples 
 Two cohorts of adult human brain were used to measure relative protein 
expression levels.  One cohort was obtained from the Nelson Lab and the other 
from the Reddy Lab.  Samples were received and then processed in order to lyse 
proteins and kept in 1X Laemmli sample buffer for SDS-PAGE and Western 
immunoblotting.   
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Table 2. Reagents used in experiments 
   
Reagent Company 
Catalog 
Number 
10x FASTRun Tris SDS PAGE 
Running Buffer  Fisher BP881-500 
12-well Flate Bottom Culture Plate Corning 3513 
24-well Flat Bottom Culture Plate Corning 3526 
48-well Flat Bottom Culture Plate Corning 3585 
96-well Flat Bottom Culture Plate Corning 3596 
Albumin bovine fraction V ICN Biomedicals 160069 
all-trans-retinoic acid Sigma R2625 
Ammonium persulfate amresco 0486-256 
B27 Gibco 17504-044 
Blocker™ Casein in TBS Thermo Scientific 37528 
cellgro™ Eagle's Minimum Essential 
Medium (MEM) Corning 10-010-CV 
cellgro™ RPMI 1640 Medium Corning 10-104-CV 
CellTiter-Fluor™ Cell Viability Assay Promega G6080 
CellTiter-Glo® Luminescent Cell 
Viability Assay Promega G7570 
CL-XPosure Film Thermo Scientific 34090 
Collagen  Sigma C7521 
Criterion XT Bis-Tris Gel BioRad 345-0113 
Cytotoxicity Detection Kit (LDH) Sigma-Aldrich 11644793001 
Dimethyl sulfoxide (DMSO) Santa Cruz sc-358801 
DNMT Activity/Inhibition Assay Active Motif 55006 
Donor Horse Serum Cellgro 35-030-CV 
Fetal Bovine Serum Cellgro 35-015-CV 
FGF-Basic (AA 1-155) Recombinant 
Human Protein Life Technologies PHG0264 
Gibco™ Opti-MEM™ I Reduced 
Serum Media Life Technologies 31985070 
Glutamax Life Technologies 35050061 
HDAC (Colorimetric) Assay Kit Active Motif 56210 
Hoescht stain Invitrogen H1399 
Human Aβ40 ELISA Kit Invitrogen KHB3481 
Human BDNF Recombinant Protein Cell Signaling 3897 
iBlot® Transfer Stack, PVDF, regular 
size Invitrogen IB401001 
Lipofectamine® RNAiMAX 
Transfection Reagent Invitrogen 13778030 
Luc Photo TF Activation Reporter 
Assay Signosis BA-1001 
Luciferace Assay System Promega E1500 
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Mithramycin A Santa Cruz sc-200909 
M-PER™ Mammalian Protein 
Extraction Reagent Thermo Scientific 78501 
MTM-SDK Ratan Lab  
MTM-SK Ratan Lab  
Neurobasal Medium Life Technologies 12348-017 
Neurocult NS-A Basal Media 
StemCell 
Technologies 5750 
Neuronal Growth Factor (NGF) Life Technologies 11050HNAC50 
Normocin invivogen ant-nr-1 
One-Step TF Activation Reporter Array 
I Signosis BA-0001 
Paraformaldehyde Sigma-Aldrich P6148 
Penicillin-Streptomycin Solution  Cellgro 30-001-CL 
Phosphate-Buffered Saline (10X) Cellgro 20-031-CV 
Pierce™ BCA Protein Assay Kit Thermo Scientific 23227 
Pierce™ ECL Western Blotting 
Substrate Thermo Scientific 32106 
Pierce™ RIPA Lysis & Extraction 
Buffer Thermo Scientific 89900 
Poly-ᴅ-lysine Sigma P6407-5MG 
Ponceau S Stain Fisher BP103-10 
Precision Plus Protein™ Dual Color 
Standards BioRad 161-0374 
Protease Inhibitor Complete Mini Roche 11836153001 
Qproteome Nuclear Protein Kit QIAGEN 37582 
Restore Stripping Buffer Thermo Scientific 46430 
Roscovitine Sigma R7772 
Silencer Select siRNA (APP) ambion s13318 
Silencer Select siRNA (BACE1) ambion s24218 
Silencer Select siRNA (SP1) ambion s13318 
SuperSignal™ West Femto Maximum 
Sensitivity Substrate Thermo Scientific 34095 
SuperSignal™ West Pico 
Chemiluminescent Substrate Thermo Scientific 34077 
TF Activation Profiling Plate Array I Signosis FA-1001 
Tolfenamic Acid  Sigma T0535-5G 
Tris Buffered Saline (TBS) Cellgro 46-012-CM 
Triton X-100 Sigma X100-100ml 
Trypsin-EDTA 1X Cellgro 25-053-CI 
TWEEN 20 Calbiochem 655205 
XT-MOPS BioRad 161-0788 
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III. Experimental Methods 
A. Statistical analysis 
All experiments were performed at least three times unless otherwise 
indicated.  Treatments and assay loading was done with sample randomization in 
plates and gels to avoid bias.  Experiments described were repeated to confirm 
reproducibility.  Data are expressed as mean ± s.e.m. Statistical analysis was 
performed with GraphPad Prism (version 5.04, GraphPad Software, Inc., La 
Jolla, CA, USA). Statistical significance was assumed if P ≤ 0.05.  Statistically 
significant differences were determined by ANOVA followed by post-hoc 
Dunnett’s correction for multiple comparisons.   
B. Primary tissue culture 
Cell culture models are useful, especially when the aim is to observe the 
effects of pharmacological treatments on particular cell or tissue types.  Cell 
culture models allow evaluation of secreted molecules into the culture medium 
without the factor of clearance that is present with in vivo models.  For instance, it 
may be difficult to determine if Aβ peptide measurements in an animal are due to 
a change in production or a change in clearance after an experimental 
manipulation [141].  Morphological measurements are also an advantage to 
tissue culture models, especially with the live cell imaging technology of the 
Incucyte Zoom (See Methods).  Cells form a single layer in culture, allowing 
morphology to be observed in a single plane.   
  
47 
i. Preparation of tissue culture plates 
 Tissue culture plates were coated with poly D-lysine (PDL).  Powdered 
PDL was reconstituted in sterile water at 100 µg/mL, sterile filtered, and added to 
the center of each well of the tissue culture plates.  PDL was left on the plates 
overnight in the cell culture hood under UV light.  The following day, PDL was 
removed and wells were rinsed with sterile water.  Plates were allowed to dry for 
30 min before plating cells.   
ii. Tissue culture maintenance 
Cultures were maintained in a sterile tissue culture incubator at 5% CO2 
atmosphere at 37°C.  Cell culture media was changed as needed (typically every 
2-3 days).  At the conclusion of experiments, media samples were collected, cells 
were rinsed in 1X Dulbecco’s phosphate buffered saline (PBS; Invitrogen) to 
remove traces of media protein.  Cells were then lysed in RIPA buffer. 
iii. Isolation of neurospheres 
Neurospheres have been generated from various regions of the fetal CNS 
of various individuals.  This methods section describes the broad, overall 
methodology used to generate neurospheres from human primary mixed brain 
from fetuses at a gestational age between 90-110 days (Figure 12).  Preparation 
of human primary mixed brain cultures has been previously described [139].  The 
protocol used in our laboratory was approved by the Institutional Biosafety 
Committee (IRB) of Indiana University School of Medicine in Indianapolis, IN and 
conform to NIH guidelines.  Human fetal brain tissue were obtained from legally 
elective aborted fetus from the Laboratory of Developmental Biology in Seattle, 
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WA.  Brain tissues were shipped from the abortion clinic to our research 
laboratory in cold shipping media.   
Briefly, 100 mm tissue culture plate containing 5 mL of fresh shipping 
media was placed on ice.  Brain tissue was transferred to the fresh media using a 
wide-bore siliconized Pasteur pipette.  Visible blood vessels were removed and 
cleaned tissue was sliced with a scalpel to obtain 0.5 mm sections of tissue.  
These brain tissue sections were transferred into a 50 mL PET tube containing 
10 mL trypsin-EDTA.  This tube was placed in the water bath at 37°C and shaken 
at 150 RPM for 10 minutes to enzymatically digest the tissue.  This cell mass 
was then transferred by wide-bore glass Pasteur pipette into a 15 mL PET tube 
containing 5 mL media.  The mass was then triturated 10 times to obtain a 
homogenous suspension of cells.  Tubes were centrifuged at 400 g at room 
temperature for 5 min.  Supernatant was discarded and fresh shipping media 
was added into the tubes.  This trituration and centrifugation step was repeated, 
supernatant was removed, and 3 mL fresh shipping media was added.  
Homogenate was mixed by slow pipetting with a P1000 micropipette.  The 
resulting cell suspension (20 μL) was mixed with 180 μL of sterile PBS.  A 
sample was removed for counting by trypan blue exclusion. Cells for HFN were 
plated in PDL-coated plates at this step in defined culture medium (Neurobasal 
with supplements and antibiotics).  For neurosphere culture, however, this 
suspension was placed into flasks containing NeuroCult Proliferation Media 
supplemented with bFGF (10 ng/mL).  Half media changes were made every 48 
h until cells were ready for differentiation.   
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Figure 11. Processing of human CNS. Whole CNS was enzymatically 
digested, triturated, and either plated to yield human fetal neuron (HFN) 
culture, or placed into proliferation media to isolate neurospheres.  Ray, B., et 
al. Molecular Brain 2014 (7) 63. 
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Figure 12. Neurospheres derived from human CNS.  Free floating 
neurospheres were cultured in proliferation media.  Spheres were plated in 
differentiation media on plates treated with poly-D-lysine and allowed to mature 
for 10 days before being treated with drug or transfected with siRNA. 
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Figure 13. Human neurospheres in proliferation media vs. differentiation 
media. Free floating neurospheres form adherent, single layer cultures while 
differentiating.   
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iv. Characterization of neurosphere culture  
We have previously cultured and characterized primary human neuron 
culture [142].  Neurospheres were isolated from fetal human brain tissue (Figure 
13). Cells were cultured and maintained in Neurocult NS-A Basal Media (Stem 
Cell Technologies #05750) supplemented with Neurocult proliferation 
supplement in flasks for up to 5 days (Figure 14).   
To optimize media conditions for subculturing neurospheres, 
undifferentiated neurospheres in proliferation media with and without growth 
factors were harvested at several time points; day in vitro (DIV) 7, 14, 21, and 28.  
Cells were cultured in flasks in either proliferation media alone or proliferation 
media supplemented with EGF and bFGF for 14 days.  At DIV15, BDNF was 
added to both flasks (Figure 15).  Cells were collected and lysed for use in cell 
viability analysis using the Cell Titer Glo (CTG) assay (see Methods).  
Neurospheres cultured in media containing bFGF, EGF, and BDNF show a 
significant increase in cell viability up to DIV21.  By DIV28, cell viability was 
significantly decreased, signaling that cells should not be cultured past DIV21 in 
future experiments and should always be in media supplemented by bFGF and 
EGF.  Western blot analysis was performed to demonstrate protein levels of 
nestin (neural progenitor marker), NSE (neuronal marker), and SNAP25 
(synaptic marker) in these neurospheres over time (Figure 16).  When 
supplemented with bFGF and EGF, the neuroprogenitor population was 
maintained up to 14 days and up to 21 days with the addition of BDNF.  
However, this decreases at DIV28.  The mature cell protein levels were 
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consistent across various time points and regardless of absence or presence of 
growth factor supplements.  Synaptic protein expression was significantly 
decreased at DIV21 with the addition of BDNF in cultures supplemented with 
bFGF and EGF.  In future experiments, cells were cultured closer to DIV14 and 
in media supplemented by bFGF and EGF.   
Primary neurospheres were mechanically dissociated to a single-cell 
suspension and plated in media supplemented with Neurocult differentiation 
supplement, media plus 10 ng/mL bFGF, media plus 10 ng/mL BDNF, or media 
plus 10 ng/mL bFGF and 10 ng/mL BDNF.  Cells were plated in PDL-coated 24-
well plates, and cultured at 37°C for 21 days.  Cell morphology was monitored by 
phase contrast microscopy throughout.  We collected cell lysates at two time 
points; DIV 11 and 21 for use in cell viability analysis.  CTG revealed a significant 
decrease in cell viability in all media besides Neurocult media containing 
Neurocult Differentiation Supplement (Figure 17).  This was true at both DIV11 
and DIV21.   CTG also showed that cells cultured in Neurocult media plus 
Neurocult Differentiation Supplement experience no significant change in cell 
viability after 10 days (Figure 17).  On the other hand, cells in media 
supplemented with bFGF, BDNF, or a combination of both growth factors 
experienced significant decreases in cell viability between DIV11 and DIV2.  
These data revealed that although proprietary, the differentiation supplement 
provided commercially by StemCell Technologies maintains differentiated NSCs 
with the highest cell viability compared to other growth factors.  This recipe was 
used for future experiments.   
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Cells were cultured and plated in Neurocult media plus Neurocult 
Differentiation Supplement in a 24-well format.  Cell lysate was collected from 
cells at each time point (n=4; DIV5, 10, 15, 20 plate 1; DIV30, 35, 40, 45 plate 2).  
CTG reveals a time dependent decrease in cell viability from DIV5 to DIV20 
(Figure 18).  However, cell viability increased at DIV40 before decreasing at 
DIV45.  These data showed that dNSPc can be maintained for several weeks 
with relatively high cell viability as compared to that of cells plated for only a few 
days.   
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Figure 14.  Undifferentiated neurospheres in proliferation media.  Free 
floating neurospheres in culture are clusters of neuronal stem cells.  These 
neurospheres are comprised of varying percentages of neural stem cells.  
Neurospheres such as these were dissociated and distributed evenly into 
plates in order to be differentiated for use in drug treatments.   
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Figure 15. Undifferentiated NSPc in proliferation media supplemented with 
growth factors.  Isolated undifferentiated neurospheres plated in proliferation 
media OR proliferation media plus bFGF and EGF for 14 days; BDNF added at 
DIV15.  Near 5 fold increase in cell viability of NSP from DIV7 to DIV14 when 
media was supplemented with bFGF and EGF; while no change was seen at 
this time interval in media alone 
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(a)
 
Figure 16a. Optimizing media conditions by protein levels detected by 
Western immunoblotting. When supplemented with bFGF and EGF, the 
neuroprogenitor population was maintained up to 14 days and up to 21 days 
with the addition of BDNF.  However, this population decreased at DIV28. 
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(b)
 
Figure 16b. Optimizing media conditions by protein levels detected by 
Western immunoblotting.  The mature cell protein levels were consistent 
across various time points and regardless of absence or presence of growth 
factor supplements.   
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(c)  
Figure 16c. Optimizing media conditions by protein levels detected by 
Western immunoblotting. Synaptic protein expression was significantly 
decreased at DIV21 with the addition of BDNF in cultures supplemented with 
bFGF and EGF.   
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Figure 17. Optimization of media conditions for differentiated 
neurospheres.  Media with commercially available differentiation supplement 
yielded the highest cell viability among tested conditions.   
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Figure 18. Extended culture times reveal an increase in cell viability in 
differentiated neurosphere culture. dNSPc were harvested at 8 time points.  
Cell viability significantly decreased at DIV20, yet increased at DIV40 before 
decreasing at DIV45.  These data showed that dNSPc can be maintained for 
several weeks with relatively high cell viability as compared to that of cells 
plated for only a few days.   
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v. Protein marker characterization by Western immunoblot 
 Lysates of cells maintained in neurosphere culture before differentiation 
were subjected to Western blotting to determine relative expression levels of 
relevant proteins.   
a. Undifferentiated neurosphere culture 
 Free floating neurospheres were cultured in proliferation media containing 
bFGF or bFGF plus BDNF for 14 days.  At DIV7 and 14, cells were collected, 
harvested, and lysed for SDS-PAGE and Western blot analysis.  Significant basal 
levels of the astrocytic marker GFAP were consistent from DIV 7 and 14 (blot not 
shown).  Neuronal precursor and immature markers nestin and doublecortin were 
used to assess the neuroprogenitor protein expression in these cells (Figure 19).  
Post-synaptic marker PSD95 was detected at each time point as well as 
neuronal marker NSE (Figure 20).  Amyloid pathway proteins APP and BACE1 
are detected in undifferentiated NSP (Figure 21).    
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Figure 19. CNS stem cell and neuronal precursor/immature neuronal 
marker expression of undNSPc. Western immunoblot of lysates from 
undifferentiated neurosphere culture.  Cells were allowed to proliferate in 
media supplemented with bFGF alone, or with bFGF and BDNF combined for 
up to 14 days.  Lysates were collected at two time points, DIV7 and DIV14.  
Nestin, an intermediate filament expressed in developing neurons, was 
detected at both time points.  Doublecortin is a neuronal migration protein 
expressed by immature neurons and neuronal precursors.  Consistent levels of 
doublecortin were detected at both time points as well.   
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Figure 20. Post-synaptic and mature neuronal marker expression of 
undNSPc.  Western immunoblot of lysates from undifferentiated neurosphere 
culture.  Cells were allowed to proliferate in media supplemented with bFGF 
alone, or with bFGF and BDNF combined for up to 14 days.  Lysates were 
collected at two time points, DIV7 and DIV14.  PSD95 is a scaffolding protein 
located in the post-synapse of neurons.  NSE is an enzyme found in mature 
neurons.  Both postsynaptic and mature neuronal markers were detected in 
undNSPc at DIV7 and DIV14. 
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Figure 21. High basal levels of APP and BACE1 expressed in undNSPc. 
Western immunoblot of lysates from undifferentiated neurosphere culture.  
Cells were allowed to proliferate in media supplemented with bFGF alone, or 
with bFGF and BDNF combined for up to 14 days.  Lysates were collected at 
two time points, DIV7 and DIV14.  Expression of BACE1 increased with the 
addition of BDNF to proliferation media up to DIV7 and decreased at DIV14.  
APP was detected at both time points as well. 
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b. Differentiated neurosphere culture 
 Free floating neurospheres were differentiated as previously mentioned for 
14 days, lysed, and proteins were separated by SDS-PAGE.    Astrocytic and 
synaptic proteins were also detected in differentiated cultures along with 
neuronal markers (Figure 22).  Western immunoblotting was used to detect 
amyloid-pathway proteins APP and BACE1 (Figure 23). 
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Figure 22.  DIV 10 differentiated neurosphere culture.  Free floating 
neurospheres in proliferation media were dissociated and counted.  Cells were 
then transferred to differentiation media and plated at a density of 150,000 
cells/well for 10 days.   
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Figure 23. Western blot analysis shows human differentiated 
neurospheres express synaptic, neuronal, and astrocytic protein at Day 
14. Proteins of the amyloid pathway, APP and BACE1 were detected in 
dNSPc.  There was synaptic protein expression as detected by synaptophysin 
and SNAP25.  Neuronal marker NSE levels were also detected in dNSPc.  
GAPDH was used as a loading control.   
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vi. Location of proteins by immunocytochemistry 
Cells were fixed and stained as described above for ICC.  Three time 
points of DIV7, 14, 21 were chosen (Figure 24).  GFAP, pan-neuronal and 
nuclear (Hoechst) antibodies were used to visualize their localization and relative 
abundance in dNSPc culture (Figure 25).  The astrocytic (GFAP+) population 
was maintained in differentiated neurospheres through Day 21 while the pan-
neuronal (somatic, nuclear, dendritic, axonal protein marker cocktail) population 
decreased by Day 14. 
vii. Assessment of cell phenotype by flow cytometry 
 Neuronal, glial, and other relevant antibody markers were used to assess 
the different cellular populations in the neurosphere cell cultures.  Cells were 
fixed using 4% paraformaldehyde and permeabilized with 0.25% Triton X-100.  
Cells were then blocked with 10% horse serum and incubated overnight with the 
primary antibody of choice.  Appropriate corresponding secondary antibodies and 
fluorophores were used.   
Day 7, 14, 30 were time points used to assess differentiated cultures.  The 
immature cell population as detected by nestin labeling of differentiated 
neurosphere culture decreased from nearly 60% at day 7 to almost 40% by day 
30 as measured by flow cytometry (Figure 26).  Mature cell population (NSE 
antibody labeling) of differentiated neurosphere culture appeared consistent 
(about 40%) at each time point as measured by flow cytometry (Figure 27).   
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Figure 24. Immunocytochemistry of differentiated neurospheres at DIV7, 
14, and 21.  ICC shows astrocytic (GFAP) population is maintained in 
differentiated neurospheres through Day 21; Pan-Neuronal (somatic, nuclear, 
dendritic, axonal protein marker cocktail) decreases by Day 14. 
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Figure 25. Immature cell population of differentiated neurosphere culture 
decreases from nearly 60% at day 7 to almost 40% by day 30 as measured by 
flow cytometry (Nestin labeling) 
 
 
Figure 26. Mature cell population of differentiated neurosphere culture appears 
consistent (about 40%) at each time point as measured by flow cytometry 
(NSE labeling) 
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 The population of undNSPc was analyzed by flow cytometry at DIV7 and 
14.  Addition of BDNF decreases the neuroprogenitor (double labeled GFAP and 
pan-neuronal) cell population of undifferentiated NSPc by nearly 15% 
represented by the upper right quadrant (Figure 28a).  While maximum 
maturation level of the cell population (Pan-Neuronal labeled) of undNSPc by 
Day14 (Figure 28b). 
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Figure 27a.  Population of undifferentiated NSP as detected by flow 
cytometry. Upper left quadrant represents the GFAP positive cell population, 
of which there are very few represented at both DIV7 and 14 time points.  
Addition of BDNF decreases the neuroprogenitor (double labeled GFAP and 
pan-neuronal) cell population of undifferentiated NSPc by nearly 15% 
represented by the upper right quadrant.  The lower right quadrant shows a 
pan-neuronal population that increases from DIV7 to 14. 
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Figure 27b.  Population of undifferentiated NSP as detected by flow 
cytometry. Flow cytometry shows maximum maturation level of the cell 
population of undifferentiated NSPc is achieved in proliferation media plus 
or minus BDNF by Day14 (Pan-Neuronal labeled). 
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C. Viability and toxicity assays 
i. Cell Titer-Glo 
To measure cell viability, the luciferase based Cell Titer-Glo kit (CTG; 
Promega, Madison, WI) was used to compare relative ATP concentration from 
cells in our experiments.  The CTG assay was used to detect differences in cell 
density between wells.  After cells were collected from the culture plate and 
lysed, 5 µL of lysate, 25 µL PBS, and 30 µL of CTG assay solution were added to 
a white bottom plate.  The plate was placed on an orbital shaker for 10 minutes.  
Luminescence was measured with a Glomax luminometer (Promega) and 
reported at relative light units (RLUs).   
ii. Lactose Dehydrogenase Assay 
The lactose dehydrogenase (LDH) assay was used to quantify levels of 
LDH released by cells into the medium.  LDH is a cytosolic enzyme that is 
released into the medium in proportion to the number of damaged and dead cells 
in culture.  The commercially available LDH Cytotoxicity Kit (Roche) was used 
according to manufacturer protocol.  To quantify the amount of LDH released by 
the cells, samples were compared to a standard curve of known LDH 
concentration (Figure 29).  To determine the dilution of LDH that could be 
optimally read, various concentrations of LDH were assessed and absorption 
measured for linearity of OD reading (Figure 30).   
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Figure 28.  Standard curve for LDH Assay.  In order to quantify the amount 
of LDH released by the cells, samples were compared to a standard curve of 
known LDH concentration and the corresponding OD reading detected by an 
absorbance plate reader. R-squared indicates how closely the data are to the 
fitted regression line plotted here. 
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Figure 29.  Increasing concentrations of LDH were assessed and 
absorption measured for linearity of OD reading.  Concentrations of 1 ng/µL 
and 2.5 ng/µL produce readings that are close to the fitted regression line with an 
R2 close to 1, while a concentration as high as 10 ng/µL does not.   
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In addition to optimizing the volume of conditioned media to use for 
measurement, it was imperative to understand the number of cells that lead to a 
particular reading within the linear range of the assay.  An increasing number of 
HeLa cells produce a correlative amount of LDH that is reflected in the 
measurement detected by absorbance reading (Figure 31).  An additional control 
experiment was performed to understand the expected OD reading from 
increasing numbers of injured and dying cells.  HeLa cells were plated in a 48-
well plate at increasing cell densities and cultured for 24 h (Figure 32).  Triton-X 
was added to some wells (n=3) (Figure 32a) and remaining wells (n=3) were left 
untreated (Figure 32b).  Addition of triton-X to HeLa cells increases the OD 
reading correlating to the amount of LDH released from cells into conditioned 
media.   
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Figure 30.  Cell number vs. optical depth of the LDH assay.  An increasing 
number of cells produce a correlative amount of LDH that is reflected in the 
measurement detected by absorbance reading.   
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Figure 31a. .  Increasing numbers of cells produce correlative increased 
amounts of LDH when treated with Triton-X as measured by absorbance.   
	
 
Figure 31b.  Increasing numbers of cells produce correlative increased 
amounts of LDH as measured by absorbance.  These readings are lower than 
those of cells treated with the detergent Triton-X, which damages the cell 
membrane.   
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D. siRNA Transfection 
Cultured cells were grown in 24- or 48-well plates and transfected using 
Lipofectamine RNAiMax lipid-based transfection reagent (Life Technologies) per 
the manufacturer protocol.  Transfection complexes were made using 50 µL per 
well Opti-MEM media (Gibco).  Mock transfected cells contained Opti-MEM and 
75 µL per well RNAiMax with no RNA.  Cells were transfected for 48 h at 37ºC.  
Cells were then gently washed with PBS and lysed with RIPA buffer containing 
protease inhibitor.  Protein estimation was performed using the BSA Protein 
Assay kit (Thermo).   
E. Transcription Factor Activation Reporter Arrays 
i. LucPhoto TransActivation Array 
 One-Step LucPhoto TransActivation Array was obtained from Signosis 
(Santa Clara, CA) and used according to the manufacturer protocol.  Briefly, four 
sets of 24 baculovirus recombinant viruses (30 µL) were transferred into three 
columns of cell culture wells of a 96-well plate containing cells at 70% confluency 
and incubated for 24 h. MTM or TA was added to cells for 36 h to induce 
luciferase activity.  An equal volume of CellTiter-Fluor Reagent (Promega) was 
added to add wells to measure cell viability.  Plate was allowed to incubate for 
30min at 37ºC. Fluorescence was measured at 360EX 535EM.  Media was 
removed and cells were washed with PBS.  PBS was removed and 20 µL 
passive lysis buffer was added to each well for a 15 min incubation period at 
room temperature.  Luciferase substrate (100 µL) was added to each well and 
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mixed.   Plate was immediately read in a Glomax luminometer (Promega) and 
reported as relative light units (RLUs). 
ii. Transcription Factor Activation Profiling Array 
Transcription factor activation profiling plates were obtained from Signosis 
(Santa Clara, CA) and used according to manufacturer protocol (Figure 40a).  
Each well of the plate was specifically pre-coated with complementary 
sequences of probes.  Differentiated SK-N-SH cells were treated with vehicle, 
MTM, MTM-SDK, MTM-SK, TA, and the combination of MTM with TA in 100 mm 
dishes for 48 h.  Nuclear protein extraction was performed.  Biotin-labeled probes 
that are made based on consensus sequences of TF DNA-binding sites were 
incubated with nuclear extracts.  Individual probes found the corresponding TF 
and formed TF/probe complexes.  Bound probes were then detached from the 
complex and analyzed through hybridization with the plate.  Captured DNA probe 
was then detected with streptavidin-horseradish peroxidase.  Luminescence was 
measured with a Glomax luminometer (Promega) and reported as relative light 
units (RLUs).   
F. Epigenetic Enzyme Activity Assays 
i. DNMT Activity Assay 
Kit was obtained from Active Motif and used according to manufacturer 
protocol.  Differentiated SK-N-SH cells were treated with vehicle, MTM, MTM-
SDK, MTM-SK, TA, and the combination of MTM with TA in 100 mm dishes for 
48 h.  Nuclear protein extraction was performed and protein estimation was done 
with both the cytoplasmic and nuclear fractions.  Pseudoreplicates were used to 
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measure cell viability.  To calculate the activity of DNMTs, an average of the 
pseudoreplicate readings was taken.  The average blank OD was subtracted 
from this average pseudoreplicate OD.  This quantity was then divided by the 
amount of protein added to the reaction in µg multiplied by the incubation time in 
hours.  This total was then multiplied by 1000 to give activity in OD/h/mg. 
ii. HDAC Activity Assay  
Kit was obtained from Active Motif and used according to manufacturer 
protocol.  The assay uses a peptide substrate with an acetylated lysine group 
that can be deacetylated by HDAC enzymes.  When it has been deacetylated, 
the lysine reacts with the provided developing solution to release a chromophore.  
Differentiated SK-N-SH cells were treated with vehicle, MTM, MTM-SDK, MTM-
SK, TA, and the combination of MTM with TA in 100 mm dishes for 48 h.  
Nuclear protein extraction was performed and protein estimation was done.  In 
short, all components were thawed on ice and reagents prepared according to 
protocol.  Nuclear extract was used at a concentration of 3 µL and added to 27 µl 
assay buffer to bring the test sample volume to 30 µL total.  HDAC assay buffer, 
HDAC substrate, and test sample were added to wells of the plate and incubated 
at 37°C for 30 min.  HDAC reactions were stopped with the addition of 
developing solution, and then incubated for 10 min at room temperature.  
Standard curve was created to determine enzymatic activity (not shown). The 
total amount of protein added was calculated using protein concentration and 
volume used.  Absorbance was read in a plate reader at 415 nm.  
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G. Incucyte ZOOM  
 Incucyte ZOOM technology allows real-time live microscopic imaging of 
cells in culture.  There is direct access to microscopic imaging while 
pharmacological agents have been applied directly to the cells at varying 
concentrations in culture medium.  This access allows for genetic manipulations 
via siRNA transfection and reporter assays that cannot be done in whole animal 
models.  We expect that optimization of Incucyte Zoom technology with post-
mitotic tissue culture models will be a powerful contribution to the field of AD 
study.  Plating conditions of the Incucyte Zoom were done using PC12 cells 
differentiated by NGF (Figure 33).   
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IV. Aim 1:  Mechanistic study of the activation of Alzheimer’s disease 
relevant transcription factors in human cells 
A. Introduction 
 Transcription factors have been considered as possible therapeutic 
targets for years.  Hesitation for use of TFs as drug targets is partially due to the 
fact that the interacting surface between DNA and TFs is quite large and subject 
to many changes during DNA-binding [143]. As previously discussed, SP1 has 
been shown to be relevant in neurodegenerative disorders, including AD.  
Mechanistic investigations of compounds thought to target SP1 may lead to a 
better understanding of how these compounds affect amyloid-beta pathway 
proteins.  It is also important to understand whether these drugs act solely 
through SP1 or if in fact multiple TFs are involved in a pathway leading to 
changes in APP, BACE1, and Aβ.   
B. Prediction Tools & Literature Review 
A predicted gene network of SP1 with genes of the Aβ pathway was 
analyzed according to GeneMANIA (http://www.genemania.org August 2016 
Assembly). AD-associated genes predicted to directly or indirectly interact with 
SP1 and other TFs were shown (Figure 33). Connections include genetic and 
physical interactions, co-localization, and co-expression.  For example, ATF6 
(Activating transcription factor 6) showed a genetic interaction with SP1.  ATF6 
has been implicated in the accumulation of misfolded proteins in diseases such 
as AD [144].  Brains from deceased individuals with Down syndrome were 
examined and up-regulation of E2F-1 was observed, exhibiting similar 
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neuropathological features of dementia of Alzheimer’s type [145].  E2F-1 shares 
a pathway with SP1 and co-localizes with SP1 according to the gene prediction 
tool (Figure 33).  Additionally, subcellular distribution of E2F-1 has been shown to 
be altered during AD [146].  The angiogenic TF Ets-1 was observed to be 
differentially expressed in AD brain versus control brains.  Control brains showed 
little expression of Ets-1 whereas Ets-1 was ubiquitously expressed in the cortex 
and hippocampus of AD brain tissue [147].  Prediction tools along with an 
extensive literature review led to a working list of genes and TFs implicated in 
neurodegeneration and AD (Table 3).   
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Figure 32. Predicted gene network of SP1 and APP.  Connections include 
genetic and physical interactions, co-localization, and co-expression.  Many 
TFs of interest can be generated from prediction tools (GeneMANIA.org). 
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Table 3. Genes related to Alzheimer’s disease by literature review 
Name Full Name Aliases Role of Protein Relevance to AD 
APBA1 amyloid beta 
(A4) precursor 
protein-binding, 
family A, 
member 1 
MINT1, X11A, 
adapter 
protein 
X11alpha, 
D9S411E, 
LIN10 
(GeneCards, 
Sept 2016) 
Neuronal adaptor 
protein; involved 
in signal 
transduction; 
synaptic vesicle 
exocytosis by 
binding to 
Munc18-1 
(GeneCards, Sept 
2016) 
Stabilizes APP; 
inhibits production 
of proteolytic APP 
fragments (RefSeq, 
Jul 2008) 
APBB1 amyloid beta 
(A4) precursor 
protein-binding, 
family B, 
member 1  
RIR, FE65 
(GeneCards, 
Sept 2016) 
Adaptor protein; 
located in the 
nucleus; 
transcription 
coregulator; binds 
modified histones 
(UniProtKB, Sept 
2016) 
Forms 
transctriptionally 
active complex with 
gamma-secretase-
derived APP 
intracellular domain 
(Entrez, Sept 2016) 
APP amyloid beta 
(A4) precursor 
protein 
AD1, CVAP, 
Peptidase 
Nexin, AAA 
(GeneCards, 
Sept 2016) 
Cell surface 
receptor; involved 
in neurite growth, 
neuronal 
adhesion, 
axonogenesis and 
cell mobility 
(UniProtKB, Sept 
2016) 
Mutations in APP 
have been 
implicated in 
autosomal 
dominant AD; 
progressive 
cleavage can lead 
to amyloid-beta 
production (Tocris, 
Sept 2016) 
ATF6 activating 
transcription 
factor 6  
ATF6A 
(GeneCards, 
Sept 2016) 
Transcription 
factor; activates 
target genes for 
the unfolded 
protein response 
during ER stress 
(Entrez, Sept 
2016) 
Neuronal death in 
AD may arise from 
ER dysfunction  
(Katayama et al., 
2004) 
CREB cAMP 
response 
element-
binding protein 
CREB-1 Transcription 
factor; binds to 
cAMP response 
elements (CRE) 
[148]  
Critical role in 
memory 
consolidation [149] 
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E2F1 E2F 
transcription 
factor 1 
RBBP3, 
RBAP1, PBR3 
(GeneCards, 
Sept 2016) 
Transcription 
activator; binds 
DNA; mediates 
cell proliferation 
and TP53-
dependent 
apoptosis  
(UniProtKB, Sept 
2016) 
E2F1 mediates 
death of amyloid-
beta-treated cortical 
neurons (Jordan-
Sciutto et al., 2001) 
ETS1 v-ets avian 
erythroblastosis 
virus E26 
oncogene 
homolog 1 
EWSR2 
(GeneCards, 
Sept 2016) 
Transcription 
factor; controls 
expression of 
various cytokine 
and chemokines 
(UniProtKB, Sept 
2016) 
Differentially 
expressed in AD 
brain versus 
controls [147] 
HIF1 hypoxia-
inducible 
factor-1 
HIF1; MOP1; 
PASD8; HIF-
1A; bHLHe78; 
HIF-1alpha 
(GeneCards 
Mar 2017) 
Respond to 
decreases in 
available oxygen 
in the cellular 
environment [150] 
Stabilization of 
HIF1 levels is 
neuroprotective 
[151] 
IDE insulin 
degrading 
enzyme 
Abeta-
Degrading 
Protease, 
insulin 
(GeneCards, 
Sept 2016) 
Zinc 
metallopeptidase; 
degrades insulin 
(Entrez, Sept 
2016) 
Degrades amyloid 
formed by APP; 
Deficiencies are 
associated with AD 
(UniProtKB, Sept 
2014) 
IL1A interleukin 1 
alpha 
IL1, IL1F1 
(GeneCards, 
Sept 2016) 
Cytokine involved 
in various immune 
responses 
(Entrez, Sept 
2016) 
Induces synthesis 
and processing of 
APP (Griffin et al., 
1995) 
MME membrane 
metallo-
endopeptidase 
CALLA, NEP, 
neprilysin 
(GeneCards, 
Sept 2016) 
Acute lymphocytic 
leukemia antigen; 
neutral 
endopeptidase 
(Entrez, Sept 
2016) 
Amyloid-beta 
degrading enzyme ; 
regulation of 
neuropeptide 
signaling; levels are 
lower in AD brains 
(Akiyama et al., 
2001) 
NCSTN nicastrin  ATAG1874, 
KIAA0253 
(GeneCards, 
Sept 2016) 
Type I 
transmembrane 
glycoprotein ; 
component of 
gamma-secretase 
complex (Entrez, 
Sept 2016) 
Subunit of gamma-
secretase which 
cleaves  APP 
(UniProtKB, Sept 
2014) 
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NFAT nuclear factor 
of activated T-
cells 
NFAT1; 
NFATP; 
NFATC2 
(GeneCards 
Jan 2017) 
Induction of  gene 
transcription 
during the immune 
response  
Expressed by 
microglia which are 
stimulated by Aβ 
[152] 
NFκB nuclear factor 
kappa-light-
chain-enhancer 
of activated B 
cells 
p50; KBF1; 
p105; EBP-1; 
CVID12; NF-
kB1 
(GeneCards, 
Mar 2017) 
Transcription 
regulator activated 
by various intra- 
and extra-cellular 
stimuli 
Involved in Aβ-
induced 
neuroinflammation 
[153] 
PSEN1 presenilin 1  AD3, PS1, 
FAD, PSNL1 
(GeneCards, 
Sept 2016) 
Catalytic subunit 
of the gamma-
secretase 
complex 
(UniProtKB, Sept 
2016) 
Patients with 
inherited AD carry 
mutations in 
PSEN1 or APP 
which lead to 
increased amyloid 
production (Entrez, 
Sept 2014) 
SMAD  BSP1; JV41; 
BSP-1; JV4-1; 
MADH1; 
MADR1 
(GeneCards 
Mar 2017) 
signal transducers 
and transcriptional 
modulators that 
mediate multiple 
signaling 
pathways 
Colocalizes with 
both neurofibrillary 
tangles and β-
amyloid plaques 
[154, 155] 
SP1 Specificity 
protein 1 
 involved in cell 
differentiation, cell 
growth, apoptosis, 
immune 
responses, 
response to DNA 
damage, and 
chromatin 
remodeling 
Regulates 
expression of APP 
and BACE1 [78] 
STAT1 signal 
transducer and 
activator of 
transcription 1 
CANDF7; 
IMD31A; 
IMD31B; 
IMD31C; 
ISGF-3; 
STAT91 
(GeneCards, 
Mar 2017) 
activated by 
various ligands; 
mediates the 
expression of a 
variety of genes 
Binding sites 
present on the APP 
promoter [156] 
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TNF tumor necrosis 
factor 
TNFA, 
TNFSF2 
(GeneCards, 
Sept 2016) 
Proinflammatory 
cytokine; involved 
in regulation of 
cell proliferation, 
differentiation, 
apoptosis (Entez, 
Sept 2016) 
Neuroprotective in 
mice (RefSeq, Jul 
2008); located near 
a chromosomal 
region (∼30 Mb on 
6p21) that has 
shown genetic 
linkage and 
association with AD 
(Bertram and Tanzi, 
2004) 
TTR transthyretin PALB, CTS1 
(GeneCards, 
Sept 2016) 
A CSF protein; 
Carrier protein; 
transports thyroid 
hormones (Entez, 
Sept 2016) 
Lower 
concentrations of 
TTR in AD patients 
versus controls 
(Serot 2016) 
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C. Association Analysis 
The genetic data in the Alzheimer’s Disease Neuroimaging Initiative 
(ADNI) dataset, initiated in 2003 by the National Institute of Aging (NIA) has 
provided a source for quantitative endophenotype association studies [157].  A 
goal of ADNI studies has been to establish magnetic resonance imaging (MRI) 
and positron emission tomography (PET) imaging measures, as well as 
additional biomarkers from blood and cerebrospinal fluid (CSF), to influence 
eventual design of AD clinical trials [157].  We chose single nucleotide 
polymorphisms (SNPs) within the SP1 gene from the ADNI genome wide 
association study (GWAS) data and performed an association analysis with an 
AD-specific imaging biomarker (entorhinal cortex thickness).  We identified a 
significant SNP (rs11170553) associated with entorhinal cortex (ERC) thickness. 
The ERC is known to be affected in early AD.  It has been shown that AD 
subjects with thinner ERC demonstrate lower baseline cognitive scores and 
higher disease severity [158] and that reduction of ERC thickness of MCI patients 
can predict decline over time [159].  SNP rs11170553 was also associated with 
cerebral amyloid deposition (Figure 34).  
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Figure 33. Association results of SNPs in SP1 with an AD-specific 
neuroimaging phenotype (entorhinal cortex thickness).  Single nucleotide 
polymorphisms (SNPs) within ±20 kb of the SP1 gene were used and 
rs11170553 was significantly associated with entorhinal cortex thickness after 
multiple comparison adjustment. Source: ADNI dataset 
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D. Results 
i. Human Fetal Neurons  
To measure the activation of multiple TFs in human neurons, HFN were 
transduced with recombinant viruses containing a particular TF (Figure 35).  Four 
sets of 24 baculovirus recombinant viruses (30 µL) were transferred into three 
columns of cell culture wells of a 96-well plate containing cells at 70% confluency 
and incubated for 24 h. MTM was added to cells for 36 h to induce luciferase 
activity (Signosis, Inc.).  Conditioned media was removed and placed in a new 
96-well plate for cell toxicity to be measured by LDH assay.  Luciferase reporter 
activity was read by a luminometer. 
a. Effect of mithramycin A on cell toxicity of HFN 
 Cells treated with MTM (5 µM) changed cytotoxicity variably based on 
which TF construct was transduced into corresponding wells (Figure 36).  Only 
cells transduced with AP1, PPARγ, and HIF1 corresponded to a decrease in 
cytotoxicity after treatment with MTM.  SMAD-transduced cells and the CMV 
control showed no change in cell toxicity after MTM treatment.     
b. Effect of mithramycin A on transcription factor activation of HFN 
 MTM decreased activation of few TFs in HFN (Figure 37).  Notably, NFκB, 
NFAT, NRF2/ARE were decreased in luciferase activity by treatment with MTM.  
SP1 activation between vehicle and MTM treated cells was not different.  
Treatment with MTM increased activation of SMAD by nearly two-fold.   
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Figure 34.  Transcription Factor Activation Profiling in neurons.  Plate 
map of transcription factor. 3x 8 well strip, 4 reactions per TF.  24 recombinant 
viruses generated from insect cells with a modified baculovirus system that 
contains mammalian delivery element, TF consensus sequence, and 
luciferase reporter gene.  Source: Signosis, Inc. 
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Figure 35.  Effect of Mithramycin A treatment on human fetal neuron 
cytotoxicity. Cells treated with MTM (5 µM) changed cytotoxicity variably 
based on which TF construct was transduced into corresponding wells. Cells 
transduced with AP1, PPARγ, and HIF1 corresponded to a decrease in 
cytotoxicity after treatment with MTM.  SMAD-transduced cells and the CMV 
control showed no change in cell toxicity after MTM treatment. 
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Figure 36. Effect of MTM on luciferase expression of various transcription 
factors in human fetal neurons.  MTM decreased activation of few TFs.  In 
particular, NFκB, NFAT, NRF2/ARE were decreased in luciferase activity by 
treatment with MTM.  SP1 activation between vehicle and MTM treated cells 
was not different.  Treatment with MTM increased activation of SMAD by nearly 
two-fold.   
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ii. Differentiated Neuroblastoma Cells 
To measure the activation of multiple TFs and elucidate the status of 
signaling pathways after MTM or TA treatment, a TF reporter assay was 
performed in differentiated human neuroblastoma cells.  First, were transduced 
with recombinant viruses as described earlier (Figure 35).  Four sets of 24 
baculovirus recombinant viruses (30 µL) were transferred into three columns of 
cell culture wells of a 96-well plate containing cells at 70% confluency and 
incubated for 24 h. MTM or TA was added to cells for 36 h to induce luciferase 
activity (Signosis, Inc.).  Conditioned media was removed and placed in a new 
96-well plate for cell toxicity to be measured by LDH assay.  Luciferase reporter 
activity was read by luminometer. 
a. Effect of mithramycin A on cell toxicity of NBRA  
 Neurons transduced with IRF, SP1, and SRF showed increased 
cytotoxicity compared to vehicle treatment (Figure 38a).  YY1, NRF2/ARE, and 
XPB1 transduced cells showed a decrease in cell toxicity.  Others showed no 
change in toxicity as compared to vehicle.   
b. Effect of mithramycin A on transcription factor activation of NBRA 
MTM treatment led to nearly 80% decrease in SP1 reporter activity 
compared to vehicle treatment (Figure 38b). Several other TFs were decreased 
in activity by MTM treatment, including NFκB, NFAT, ER, AP1, and HIF1. 
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c. Effect of tolfenamic acid on cell toxicity of NBRA  
 Neurons transduced with XBP1 showed decreased cytotoxicity as 
detected by LDH assay (Figure 39a).  Transduction by other TFs was well 
tolerated with and without TA treatment.   
d. Effect of tolfenamic acid on transcription factor activation of NBRA 
TA treatment led to no change in SP1 reporter activity (Figure 39b).  
Several TFs showed no change in activation after treatment with TA.  However, 
NFκB was shown to be activated by TA treatment in NBRA.   
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Figure 37a.  Effect of MTM on cell toxicity in differentiated neuroblastoma 
cells as measured by LDH assay.  Neurons transduced with IRF, SP1, and 
SRF showed increased cytotoxicity compared to vehicle treatment.  YY1, 
NRF2/ARE, and XPB1 transduced cells showed a decrease in cell toxicity.  
Others showed no change in toxicity as compared to vehicle. 
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Figure 37b. Effect of MTM on luciferase expression of various 
transcription factors in differentiated neuroblastoma cells.  Four sets of 24 
baculovirus recombinant viruses (30 µL) were transferred into three columns of 
cell culture wells of a 96-well plate containing cells at 70% confluency and 
incubated for 24 h. MTM or TA was added to cells for 36 h to induce luciferase 
activity. MTM leads to nearly 80% decrease in SP1 reporter activity. 
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Figure 38a. Effect of TA on cell toxicity in differentiated neuroblastoma 
cells as measured by LDH assay.  Neurons transduced with XBP1 showed 
decreased cytotoxicity as detected by LDH assay.  Transduction by other TFs 
was well tolerated with and without TA treatment.   
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Figure 38b. Effect of TA on luciferase expression of various transcription 
factors in differentiated neuroblastoma cells. Four sets of 24 baculovirus 
recombinant viruses (30 µL) were transferred into three columns of cell culture 
wells of a 96-well plate containing cells at 70% confluency and incubated for 24 
h. MTM or TA was added to cells for 36 h to induce luciferase activitySeveral 
TFs showed no change in activation after treatment with TA, including SP1.  
However, NFκB was shown to be activated by TA treatment in NBRA. 
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e. Effect of mithramycin A and tolfenamic acid on transcription factor 
activation of NBRA 
 In order to directly assess the differences in TF activation between MTM 
and TA, a TF profile array was performed as depicted in Figure 40a.  In this 
experiment, 48 TFs were examined in NBRA treated with either MTM or TA 
(Figure 40b).  Several TFs including Brn-3, CAR, HIF, NFE2, and p53 show a 10-
fold change or higher in activation in MTM vs TA treated neurons.  FAST-1, IRF, 
and STAT5 all show a 5-fold change or higher.   
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Figure 39a. Transcription factor profile array. Biotin-labeled probes that are 
made based on consensus sequences of TF DNA-binding sites were incubated 
with nuclear extracts.  Individual probes found the corresponding TF and 
formed TF/probe complexes.  Bound probes were then detached from the 
complex and analyzed through hybridization with the plate.  Captured DNA 
probe was then detected with streptavidin-horseradish peroxidase. (Figure 
from Signosis Inc.) 
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Figure 39b. Transcription factor profile array.  An array of various TFs 
shown on the x-axis with the corresponding activation after treatment with MTM 
or TA measured by relative luminescence units (RLU) on the y-axis.  Several 
TFs including Brn-3, CAR, HIF, NFE2, and p53 show a 10-fold change or 
higher in activation in MTM vs TA treated neurons.  
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E. Discussion  
Treatment of a mixed brain cell culture system such as HFN with MTM 
yielded unexpected results in the activation of various TFs (Figure 37).  Although 
SP1 activity was decreased by treatment with MTM in NBRA, it is unchanged in 
HFN.  In a culture solely comprised of mature neurons, treatment with MTM 
decreases SP1 reporter activity as hypothesized.  The effect of glia and other 
cells in a mixed brain culture on the activation of TFs could be a cause of these 
differences.  For instance, it is known that particular cells of the CNS express 
certain TFs.  Microglia express the pro-inflammatory transcription factor, NFAT 
[152].  Neurons may secrete factors which induce the expression of TFs by 
astrocytes [160].  The influence of neurons on glia and vice versa in a mixed 
brain culture such as HFN may complicate the direct effects we see from a 
simple reporter assay.  Nevertheless, the NBRA culture allows us to observe the 
effects of two so-called SP1-modulating drugs, MTM and TA in a purely neuronal 
model.   
Treatment with MTM led to a decrease in NFκB activity, yet treatment with 
TA resulted in an increase.  This trend was observed in several of the TFs also 
predicted to be relevant of AD.  The transcription factor profile array allowed 
head to head comparison of the effects MTM and TA have on various TFs 
(Figure 40b).  Along with SP1, several other TFs show a decrease in activation 
when treated with MTM and no change with TA treatment.  TFs of interest show 
a decrease with MTM treatment and a corresponding decrease (or no change) 
with TA treatment, binding sites on AD-related gene promoters, or found in the 
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literature to be relevant to AD.  Understanding how these drugs differentially 
modulate various TFs may help elucidate a mechanism of action for these 
compounds relevant to AD.   
Transcription factor modulation by small compounds can be achieved by 
four main strategies [143].  The first strategy involves the inhibition of protein-
protein interactions, since many TFs rely on co-factors in order to function 
appropriately. Blocking TF binding to DNA requires detained understanding 
about the binding surface of the ligand.  Small, clearly defined protein surfaces 
are ideal.  Directly targeting and manipulating the TF DNA binding domain (DMD) 
by small molecules to either change its conformation of prevent DNA binding is 
yet another approach.  TA has been shown to promote the degradation of SP1 
[161].  Another strategy involves the targeting of chromatin remodeling/epigenetic 
reader proteins, which are essential for the access of TFs to DNA access. The 
fourth approach is based on compounds that would compete with TFs to block 
protein-DNA binding or by altering the conformation of target DNA sequences 
such that they cannot be recognized by TFs.  MTM is thought to compete with 
and displace SP1 from its binding sites.  The work presented here indicates that 
not only do MTM and TA activate SP1 differently; they also activate several other 
TFs.  This function speaks to their differences in mechanism of action and the 
possibility of multiple networks of TFs involved in their action on amyloid pathway 
genes.   
There is great future potential in compounds that work by any of these 
approaches. An HSP60-binding compound has been created, which prevents 
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HIF1 activation, likely by HIF1α crosslinking [162]. Another compound, inS3-54 
inhibits transcriptional activity of STAT3 [163].  Understanding the molecular 
mechanisms of TF activation and function will inevitably provide clues how 
modulating specific TF function by drugs such as MTM and TA can be achieved 
and possibly also applied for AD therapy. 
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V. Aim 2:  Examination of the effects of transcription factor modulating 
compounds on epigenetic markers in human neurons 
A. Introduction 
Epigenetic mechanisms are involved in the regulation of processes related 
to memory consolidation, aging, and cognition during the normal lifespan [164]. 
Environmental factors may play a role in the interaction with specific loci by 
modifying their expression through epigenetic mechanisms to increase 
susceptibility to disorders later in life [80, 165, 166].  Lifestyle, genetic factors, 
and environmental exposures in early life may all influence the epigenome in a 
latent manner [167, 168].  Possible treatments could target particular pathways 
associated with dysfunction.  DNA methylation, chromatin modifications, and 
even microRNA expression have all been shown to be altered in 
neurodegenerative disorders.  DNA methylation takes place when a methyl group 
is added at CpG dinucleotides which can	activate or repress the transcriptional 
activity of a gene [169].  Histone deacetylaces (HDACs) are involved in the 
regulation of histones and many neurological processes [170].  For example, 
DNA hypomethylation leads to expanded regulation of the TF NFκB [171]. 
Understanding how certain compounds influence methylation and/or histone 
modification is important for understanding how TF binding may be affected by 
them.  The experiments described in this section sought to discover the effect 
treatment with SP1-modulating compounds would have on histone deaceylase 
activity or DNA methyltransferase (DNMT) activity in human cells.  Differentiated 
SK-N-SH (NBRA) cells were treated with vehicle, MTM, MTM-SDK, MTM-SK, 
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TA, and the combination of MTM with TA in 100 mm dishes for 48 h.  Nuclear 
protein extraction was then performed. 
B. Results 
i. Effect of drug treatment on SP1 expression levels in nuclear extract 
Nuclear extracts from NBRA treated with compounds showed variation in 
SP1 protein levels via Western immunoblotting (Figure 41).  GAPDH was used 
as a loading control and levels of SP1 for each sample were normalized to the 
corresponding GAPDH level for that sample.  MTM treated neurons as well as 
those treated with combination MTM and TA showed a significant decrease in 
SP1 as compared to vehicle.  Cells treated with analog MTM-SK and those 
treated with TA showed an increase in SP1 levels.    
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Figure 40. Effect of treatment of differentiated neuroblastoma cells with 
MTM, its analogs, and TA on levels of SP1. Nuclear extracts from NBRA 
treated with compounds show variation in SP1 levels.  Lower levels were 
detected in the cytosolic fraction (not shown).  MTM treated neurons as well as 
those treated with combination MTM and TA show a significant decrease in 
SP1 as compared to vehicle.  Cells treated with analog MTM-SK and those 
treated with TA showed an increase in SP1 levels.   
  
113 
ii. Effect of drug treatment on DNMT activity 
 Retinoic acid-differentiated neurons (NBRA) were treated with compounds 
for 48 h. Cells were harvested and nuclear protein was extracted to measure 
DNMT activity.  MTM-SDK significantly reduced DNMT activity in these neurons 
(Figure 42). 
iii. Effect of drug treatment on HDAC activity 
Neurons (NBRA) were treated with compounds for 48 h. Cells were 
harvested and nuclear protein was extracted to measure HDAC activity.  MTM-
SDK significantly reduced HDAC activity in neurons (Figure 43). 
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Figure 41.  DNMT activity is significantly decreased in neurons treated 
with MTM-SDK. A sensitive ELISA-based enzyme activity assay using the high 
affinity binding of methyl CpG binding domain (MBD) protein towards 
methylated DNA to detect DNA methyltransferase activity on the provided 
CpG-enriched DNA substrate was used per manufacturer protocol.  Methylated 
DNA was recognized by His-tagged MBD in amounts proportional to enzyme 
activity.  An HRP-conjugated polyhistidine antibody provided the readout via 
spectrophotometer (OD/h/mg).  Differentiated SK-N-SH cells were treated with 
vehicle, MTM, MTM-SDK, MTM-SK, TA, and the combination of MTM with TA 
in 100 mm dishes for 48 h.  Nuclear protein extraction was performed and 
protein estimation was done with both the cytoplasmic and nuclear fractions.  
Pseudoreplicates were used (n=3).  To calculate the activity of DNMTs, an 
average of the pseudoreplicate readings was taken.  The average blank OD 
was subtracted from this average pseudoreplicate OD.  This quantity was then 
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divided by the amount of protein added to the reaction in µg multiplied by the 
incubation time in hours.  This total was then multiplied by 1000 to give activity 
in OD/h/mg. 
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Figure 42.  Treatment with SP1 modulating drugs does not significantly 
change histone deacetylase activity (HDAC) in neurons.  The assay uses a 
peptide substrate with an acetylated lysine group that can be deacetylated by 
HDAC enzymes.  When it has been deacetylated, the lysine reacts with the 
provided developing solution to release a chromophore.  Differentiated SK-N-
SH cells were treated with vehicle, MTM, MTM-SDK, MTM-SK, TA, and the 
combination of MTM with TA in 100 mm dishes for 48 h.  Nuclear protein 
extraction was performed and protein estimation was done.  Nuclear extract 
was used at a concentration of 3 µL and added to 27 µl assay buffer to bring 
the test sample volume to 30 µL total.  HDAC assay buffer, HDAC substrate, 
and test sample were added to wells of the plate and incubated at 37°C for 30 
min.  HDAC reactions were stopped with the addition of developing solution, 
and then incubated for 10 min at room temperature.  Standard curve was 
created to determine enzymatic activity (not shown). Absorbance was read in a 
plate reader at 415 nm. 
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C. Discussion 
DNA methylation is a key epigenetic mechanism regulating gene 
expression.  Understanding changes in the methylation state of the promoters of 
AD-relevant genes will provide insight into how to manipulate epigenetic 
modifications by various compounds.  It is unknown if MTM-SDK treatment leads 
to hypomethylation of SP1 or possibly the promoter regions to which SP1 binds.  
It would also be imperative to understand whether this possible hypomethylation 
would enhance or inhibit SP1 or other TF binding.  Moreover, understanding the 
cross-talk between TFs of interest and epigenetic programs will be critical in our 
understanding of how to manipulate these interactions and decrease amyloid-
beta production.  The effect MTM-SDK may have on the epigenetic state of the 
APP, BACE1, and other AD-relevant promoters may involve affecting how TFs 
such as SP1 bind and regulate their activity.   
The idea of “undoing epigenetics” is a concept worth investigating as 
modifications that altered gene expression in early life may be reversible later in 
life {Weaver, 2005 #643}.  DNMTs can be activated during both childhood and 
adulthood, and this plasticity can possibly be manipulated by compounds that 
target transcription regulators such as TFs.   
Ultimately, a mechanism of epigenetic control involving the APP or BACE1 
promoter, which potentially can be targeted by tailored small molecules toward 
TFs could be groundbreaking for AD research.  The TFs themselves may not be 
the target, but the epigenetic regulation of the binding of that TF may serve a 
better approach.  Elucidating the methylation status before and after treatment 
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with these compounds will be an important next step in evaluating the utility of 
MTM-SDK for AD.  As DNA methylation status varies between cell type [172], it 
will be critical to test the effects of these drugs in other human cell culture models 
to discover any changes in methyltransferase and HDAC activity also.  
Association studies investigating a link between methylation status of AD-
relevant promoters and AD-relevant phenotypes would also be valuable 
information to build a case for MTM or its analog MTM-SDK in AD therapy, as 
well as finding the roles of possible variants in altering TF binding.  These 
epigenetic alterations are both dynamic and reversible, making these 
mechanisms attractive for future small compound discovery.    
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VI. Aim 3:  Testing the effects of TF-modulating compounds on human 
glial, neuronal, and primary mixed brain cultures 
A. Introduction  
Cell lines derived from malignant brain tumors have been used in 
neuroscience studies for years.  However, using primary brain and neuron 
cultures is more useful when trying to mimic the biological behavior of these cells 
and trying to avoid artifacts that may arise from using immortalized cells.  Most 
neuronal cultures come from rodent brains, mostly because of their availability 
and cost [173].  Rodents do not, however, develop AD or other 
neurodegenerative diseases, which is a downside of these models.  Use of 
human neurons from induced pluripotent stem cells and cultures from nonhuman 
primates are other more expensive options for models in AD study [142].  
Recently, our laboratory was able to outline a protocol for the preparation and 
use of a human primary mixed brain culture derived from human fetal brain that 
has been successfully used in current work [142, 174].  Human fetal neurons are 
useful in AD studies, yet these cells, once plated, cannot be serially passaged or 
propagated for future experiments.  For this reason, we have begun isolating 
free-floating cultures of neural stem cells from human fetal brain tissue (See 
Methods).  These free-floating cultures are called neurospheres.  In 1992, 
Reynolds and Weiss isolated and expanded undifferentiated neurospheres and 
were able to dissociate these cells to form more secondary spheres [175, 176].  
These methods have been extensively used by research groups in numerous 
studies in animal models.  However, this system is used for the production of 
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human neural cells in culture that can be frozen, stored, thawed, and cultured 
again to provide a supply of neurons with banking potential for future 
experimental use.  These 3D neurospheres can also be induced to differentiate 
to form a monolayer of major CNS cell types using various growth factors [177-
180]. We seek to further elucidate the identity and stemness of human NSPc.  
Our studies further characterized these differentiated cells and the conditions 
needed to optimize its use as a model for AD study.   
In addition, use of the differentiated neuroblastoma cell line SK-N-SH 
(NBRA) as a post-mitotic human model allows us to easily manipulate neurons in 
a cancer cell line system.  In contrast to the dNSPc model, NBRA are not a 
mixed population culture.  Use of mature, differentiated neurons also permits the 
study of the neurobiology of these cells via real time live cell culture imaging with 
Incucyte Zoom technology (see Methods), assess amyloid beta levels via specific 
sandwich ELISA, and detect protein levels by Western immunoblotting. 
B. Results 
i. Drug dosage studies 
 Preliminary drug studies were performed in unique dividing cell lines to 
observe the effect of cell viability and toxicity across cell types.  It was imperative 
to know if partial inhibition of BACE1 or APP via SP1 modulation could allow 
reduction of Aβ without mechanism-based toxicities from its action on other 
substrates.  Also, use of purely neuronal (NBRA) and glial (U373) cell culture 
models provided insight into how these compounds affect particular cell types. 
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a. Human glioblastoma cells 
 The human glioblastoma cell line U373 was used in several preliminary 
studies along with NBRA to demonstrate which doses could be tolerated and 
used in future experiments.  U373 were plated in 24-well plates at 70% 
confluency in MEM supplemented with 10% FBS and 1X antibiotic.  Cells were 
treated with vehicle (0.01% DMSO), 0.05, 0.1, 0.5 1.0, and 10.0 µM MTM (Figure 
44a) or vehicle (0.01% DMSO), 0.1, 1.0, 10.0, 50.0 and 100.0 µM TA (Figure 
44b) for 16 h and 24 h.  Cell toxicity was measured via LDH cytotoxicity assay as 
previously described at 2 time points.  Treatment with increasing doses of MTM 
does not produce a dose-dependent increase in LDH production.  At 16 h, higher 
doses in fact decrease cytotoxicity in U373.  Although there are fluxations in LDH 
at increasing doses at the 24 h time point at the highest dose (10 µM), toxicity is 
20% less than the lowest dose of MTM.  Toxicity greatly increases at the 10 µM 
dose of TA at both time points in U373.  Lower doses of 0.1 and 1.0 µM TA are 
well tolerated in U373.   
 To discover a possible dose-dependent effect of MTM on APP, U373 were 
treated with two non-toxic doses of drug (0.5 and 1.0 µM) for 48 h.  Cells were 
harvested and Western immunoblotting was performed as previously described.  
GAPDH was used as a loading control and APP levels were normalized to it.  
APP levels are significantly decreased with MTM treatment, however, not in a 
dose dependent manner (Figure 46). Next, the effect of both MTM and TA on the 
levels of APP, SP1, and BACE1 in U373 was assessed via Western blot (Figure 
47).  U373 were plated in a 24-well plate at 70% confluency.  Cells were 
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transfected with APP, BACE1, and SP1 siRNAs as controls (n=4).  Other cells 
were treated with MTM or TA (1.0 or 5.0 µM).  Beta-actin was used as the 
loading control in this instance.  It was clear that both doses of MTM reduced 
APP levels in U373 and that TA caused no such change.  It is notable here that 
the transfection with APP siRNA reduced APP expression as well, yet SP1 
siRNA and BACE1 siRNA did not reduce their target proteins.   
b. Human neuroblastoma cells 
 Combination treatments were used to compare how MTM and TA affect 
human cells separately and in concert.  Increasing doses of MTM and TA in 
differentiation media were added to DIV7 NBRA.  Doses from 0.05 to 50,000 nM 
were used to cover a wide range.  Both cell viability and cell toxicity were 
assessed via CTG and LDH respectively (Figure 45).  Combination treatment 
decreases viability by 30% and increases toxicity by 20% of vehicle at the dose 
of 5 nM.  As expected, the toxicity and viability changes have an inverse 
relationship as peak toxicity (80% increase) is reached at 50 nM which 
corresponds to a 60% decrease in viability.     
c. Human fetal neuron culture 
The effect of these drugs on purely neuronal and glial cultures is important 
to understand, but ultimately we sought to understand their effect on the cell 
viability on primary mixed brain cultures.  HFN cultures were plated in a 24-well 
format and treated with 6 doses (0, 1, 10,100, 500, 1000nM) of MTM, TA, MTM-
SDK, MTM-SK, or combinations of MTM-SDK and TA or MTM-SK and TA for 48 
h (Figure 48). MTM analog MTM-SDK did not show a change in cell viability even 
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at higher doses and in combination with TA.  MTM-SK in combination with TA led 
to a significant decline in cell viability at the highest doses.  Mixed brain cultures 
again showed that the primary cells of different populations affected the overall 
response to SP1 modulating drugs.   
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Figure 43a.  Effect of MTM on cell toxicity in U373 as measured by the 
LDH assay. Cells were treated with vehicle (0.01% DMSO), 0.05, 0.1, 0.5 1.0, 
and 10.0 µM MTM for 16 h and 24 h. Treatment with increasing doses of MTM 
did not produce a dose-dependent increase in LDH production.   
	
 
Figure 43b. Effect of TA on cell toxicity in U373 as measured by LDH 
assay. Cells were treated with vehicle (0.01% DMSO), 0.1, 1.0, 10.0, 50.0 and 
100.0 µM TA for 16 h and 24 h. Toxicity greatly increased at the 10 µM dose. 
Lower doses of 0.1 and 1.0 µM TA were well tolerated in U373.   
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Figure 44.  Effect of MTM and TA combination treatment on the viability 
(CTG) and toxicity (LDH) of NBRA.  As expected, the toxicity and viability 
changes had an inverse relationship as peak toxicity (80% increase) was 
reached at 50 nM which corresponds to a 60% decrease in viability.     
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Figure 45. Effect of Mithramycin A on APP Expression in U373. U373 
cultured in a 12-well plate; n=4; Vehicle (0.02% DMSO), 0.5, 1.0 µM 
Mithramycin A (MTM), 48 h treatment. GAPDH was used as a loading control 
and to normalize for densitometry.  Relative APP levels were significantly 
decreased with MTM treatment, but not in a dose dependent manner.   
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Figure 46. Effect of MTM and TA on APP, SP1, and BACE1 Protein 
Expression in U373. U373 were plated in a 24-well plate at 70% confluency.  
Cells were transfected with APP, BACE1, and SP1 siRNAs as controls (n=4).  
Other cells were treated with MTM or TA (1.0 or 5.0 µM).  Beta-actin was used 
as the loading control in this instance.  Both doses of MTM reduced APP levels 
in U373 and that TA causes no such change.  Note that transfection with APP 
siRNA reduced APP expression as well, yet SP1 siRNA and BACE1 siRNA did 
not reduce their target proteins.   
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Figure 47. Effect of MTM, analogs, and TA on cell viability of human fetal 
neurons.  Human fetal neurons were treated with MTM analogs MTM-SDK 
and MTM-SK alone and in combination with TA for 48 h.  MTM analog MTM-
SDK did not show a change in cell viability even at higher doses and in 
combination with TA.  MTM-SK in combination with TA led to a significant 
decline in cell viability at the highest doses. 
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ii. Effect of transcription factor modulation on differentiated 
neurosphere cells 
a. Effect of mithramycin A and tolfenamic acid on cell viability 
 Free-floating neurospheres were transferred from proliferation media to 
differentiation media in a 24-well plate format as previously described (Methods).    
At DIV10, cells were transfected with mock, SP1 siRNA, BACE1 siRNA, or APP 
siRNA (n=4).  Cells in other wells were treated with two doses of either MTM or 
TA (n=4).  Images were captured via microscopy and cell viability measured via 
CTG (Figure 49).  SP1 inhibition by MTM, TA, or SP1 siRNA did not significantly 
affect cell viability of differentiated neurospheres as measured by CTG (Figure 
49). 
b. Effect of mithramycin A and tolfenamic acid on APP and SP1 levels 
At DIV10, dNSPc were treated with vehicle, two doses of MTM or TA (1 
µM or 5 µM) or combination treatment (1 µM) after 48 h (n=4).  Western 
immunoblot analysis revealed a decrease in both APP and SP1 levels with MTM 
treatment (Figure 50).  Combination treatment also led to a decrease in APP and 
SP1 levels in dNSPc, while TA treatment alone did not.   
130 
 
 
Figure 48. Effect of SP1 Modulation on cell morphology and viability of 
dNSPc.  At DIV10, cells were transfected with mock, SP1 siRNA, BACE1 
siRNA, or APP siRNA (n=4).  Cells in other wells were treated with two doses 
of either MTM or TA (n=4).  Images were captured via microscopy and cell 
viability measured via CTG after 48 h.  SP1 inhibition by MTM, TA, or SP1 
siRNA did not significantly affect cell viability of differentiated neurospheres as 
measured by CTG. 
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Figure 49. APP and SP1 levels measured by Western immunoblot in 
dNSPc. At DIV10, dNSPc were treated with vehicle, two doses of MTM or TA 
(1 µM or 5 µM) or combination treatment (1 µM) after 48 h (n=4).  Ponceau 
stain was used to normalize protein loading.  MTM, but not TA, treatment 
decreased APP and SP1 expression. 
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Figure 50.  APP siRNA and MTM reduce APP levels in dNSPc.  Western 
immunoblot and corresponding densitometry revealed a decrease in APP 
levels with treatment of the highest dose of MTM.  Cells were treated in sets of 
3 with error bars showing standard error of the mean. 
  
*	 *	
*	
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c. Effect of mithramycin A and tolfenamic acid on amyloid-beta 40 
levels 
The sensitive sandwich ELISA measuring Aβ40 in conditioned media of 
cells treated for 48 h revealed both doses of MTM led to significant decreases in 
Aβ40 in differentiated neurospheres (Figure 51).  By contrast, treatment with TA 
increased Aβ40 detected in dNSPc.   
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Figure 51. Specific Aβ40 sandwich ELISA. Sensitive sandwich ELISA 
measuring Aβ40 in conditioned media of cells treated for 48 h revealed both 
doses of MTM lead to significant decreases in Aβ40 in differentiated 
neurospheres. 
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iii. Effect of transcription factor modulation on differentiated 
neuroblastoma cells 
 DIV7 NBRA cells were transfected with mock or SP1 siRNA for 24 h in 
cells cultured on a 24-well plate.  A total of 12 wells were transfected with SP1 
siRNA.  Drug treatments were added the following day.  Vehicle (0.01% DMSO), 
MTM alone, TA alone, and combination MTM-TA treatment at 1 µM were added 
to cells.  MTM was added to 4 wells transfected with SP1 siRNA and TA was 
added to another set of 4 wells previously transfected with SP1 siRNA (Figure 
52).  Conditioned media was collected at 48 h after drug treatment to assess 
cytotoxicity via LDH assay.  Cells were harvested and lysed for cell viability 
reading via CTG assay.   
a. Effect of mithramycin A or tolfenamic acid alone on cell viability and 
toxicity 
 MTM or TA treatment alone did not affect viability of NBRA cells. MTM 
treatment alone did significantly increase toxicity from vehicle by nearly 20%. 
b. Effect of combination mithramycin A and tolfenamic acid treatment 
on cell viability and toxicity 
 Toxicity increased by nearly 40% in cells treated with MTM in combination 
with TA.  Cell viability was reduced to undetectably low levels by CTG.   
c. Effect of SP1 siRNA transfection on cell viability and toxicity 
 Knockdown of SP1 via siRNA alone did not change cell viability as 
compared to mock transfected cells.  Cytotoxicity was not significantly different in 
cells transfected by mock compared to those transfected by SP1 siRNA.   
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d. Effect of SP1 siRNA transfection and tolfenamic acid treatment of 
cell viability  
 Knockdown of SP1 via siRNA in combination with TA leads to a nearly 
70% LDH percent release by NBRA cells.  Cell viability was reduced to 
undetectably low levels by CTG 
e. Effect of SP1 siRNA transfection and mithramycin A treatment on 
cell viability 
 Treatment with MTM in combination with SP1 siRNA knockdown was well 
tolerated in human cells.  Cell viability was not significantly different from mock 
and no increase in toxicity was detected by LDH measurement.   
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Figure 52.  Effect of MTM and TA treatment on differentiated human 
neuroblastoma (NBRA) cells.  MTM or TA treatment alone was non-toxic in 
NBRA (NBRA) cells as measured by CTG and LDH. Knockdown of SP1 via 
siRNA alone was also non-toxic. However, MTM in combination with TA was 
toxic and knockdown of SP1 via siRNA in combination with TA was toxic. 
 
  
138 
f. Effect of mithramycin A, its analogs, and tolfenamic acid on cell 
viability of NBRA 
 Nuclear extracts from NBRA treated with compounds showed variation in 
cell viability.  MTM alone and MTM-SDK increased the cell viability (Figure 53). 
g. Effect of mithramycin A, its analogs, and tolfenamic acid on SP1 
levels by Western blot 
 Nuclear extracts from NBRA treated with compounds showed variation in 
SP1 levels (Figure 41).  MTM treated neurons as well as those treated with 
combination MTM and TA showed a significant decrease in SP1 as compared to 
vehicle.  Cells treated with analog MTM-SK and those treated with TA showed an 
increase in SP1 levels.   
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Figure 53.  Effect of MTM, MTM analogs, and TA on cell viability of NBRA 
cells. Nuclear extracts from NBRA treated with compounds show variation in 
viability.  Treatment with MTM and MTM-SDK increased cell viability as 
measured by CTG in NBRA.  ** p < 0.01 
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h. Effect of mithramycin A, its analogs, and tolfenamic acid on neurite 
branch points 
 Time (h) was separated into three stages according to inflection of slope 
of treatment. Comparisons are of slopes within a stage.  NBRA treated for 27 h 
were tracked via Incucyte ZOOM imaging.  MTM and MTM-SK maintained 
number of neurite branch points per cell body area (Figure 54). 
i. Effect of mithramycin A, its analogs, and tolfenamic acid on neurite 
length 
Time (h) was separated into three stages according to inflection of slope 
of treatment. Comparisons are of slopes within a stage.  NBRA treated for 27 h 
were tracked via Incucyte ZOOM imaging.  MTM and MTM-SK maintained 
number of neurite lengths per cell body area (Figure 55). 
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Figure 54.  Changes in neurite branch points per cell body area in NBRA 
as measured by the Incucyte Zoom.  Time (h) was separated into three 
stages according to inflection of slope of treatment. Comparisons are of slopes 
within a stage.  NBRA treated for 27 h were tracked via Incucyte ZOOM 
imaging.  MTM and MTM-SK maintained number of neurite branch points per 
cell body area. 
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Figure 55.  Changes in neurite lengths per cell body area in NBRA as 
measured by the Incucyte Zoom.  Time (h) was separated into three stages 
according to inflection of slope of treatment. Comparisons are of slopes within 
a stage.  NBRA treated for 27 h were tracked via Incucyte ZOOM imaging. 
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j. Induced pluripotent stem cell studies 
 Another valuable model for AD research includes induced fibroblasts from 
both control and AD subjects.  This model allows the same advantages of cell 
culture while providing a tissue source directly from AD patients.  Another 
advantage includes optimized, tailored media and reagents to support the 
cultures.  Cells obtained from AXOL were cultured up to DIV 16 per manufacturer 
protocol (Figure 56) and assessed at different time points for changes in cell 
viability by CTG assay.   
 Control cells were cultured up to DIV10 and treated with vehicle or MTM 
for 48 h.  Cells were harvested and lysed and assessed for cell viability via CTG 
(Figure 57).  Treatment with MTM resulted in no significant change in cell viability 
of control iPSCs as compared to those treated with vehicle.   
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Figure 56. Human iPSC-derived neural stem cell studies.  AXOL Human 
iPSC-Derived Neural Stem Cells - Alzheimer's Disease Patient (PSEN1 L286V 
mutation).  Cells were cultured for up to 16 days with cells harvested at DIV2, 
4, 6, 8, 10, 12, 14, and 16.  Cell viability of each samples (n=3) was assessed 
via CTG assay up to DIV12.   
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Figure 57. MTM in Control Patient iPSCs.  Commercially available induced 
pluripotent stem cells were cultured for 10 days and treated with MTM or 
vehicle for 48 h.  Treatment of iPSCs (control) with MTM (1 µM) showed no 
significant difference in viability versus vehicle. 
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iv. Understanding CDK5 modulation in human cells  
a. Relative expression of FOXO1, FOXO3a and CDK5 proteins in human 
neuronal and glial cell lines and primary human brain cultures 
A preliminary protein expression screen in cell lines and in lysates of 
primary brain cultures (Figure 58) revealed variable levels of forkhead box O 3a 
(Fox03a) protein in human neuronally-differentiated (HFN), glioblastoma, Jurkat 
cells and in primary human fetal brain cultures (HFB).  The PC12 lysates in these 
experiments was later found to be degraded and data was not considered.  
Neuronal cell line SK-N-SH differentiated with retinoic acid (NBRA) shows a 
distinct band at the same molecular weight at the band seen in HFN.  This band 
is also seen in the lysate of human T lymphocytes (jurkat).  It is known that 
Foxo3a can regulate the differentiation, metabolism, survival, and cell cycle 
processes and may regulate these functions uniquely in differentiated neurons 
[181].  It has been previously shown that Foxo3a shows higher expression in the 
brain than does Foxo1 [182] .  The data from the western blot in Figure 59was 
consistent with those findings as expression of FOXO1 protein levels were 
detected only in human glioblastoma (U373) and jurkat cells.  Expression of 
CDK5 protein was detected only in human glioblastoma and jurkat cells as 
shown in the western blot analysis.   
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Figure 58.  Foxo3a, Cdk5, and Foxo1 protein levels.  Western blot analysis 
of Foxo3a, Cdk5, and Foxo1 in HeLa, U373, differentiated SK-N-SH, fetal 
brain, differentiated fetal neurons and Jurkat cells.   
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b. Relative expression of FOXO1, FOXO3a and CDK5 proteins between 
human fetal brain (HFBT) and human old brain tissue specimens 
(HOBT) 
Western blot analysis of human brain samples of adult AD, and fetal 
origins revealed differences in expression of FOXO3a and CDK5 in these groups 
(Figure 59).  There was a presence of FOXO3a protein in human old but not in 
fetal brain tissue. Interestingly, however, FOXO3a was detected in differentiated 
human fetal neurons that were derived from human fetal brain tissue.  FOXO1 
could not be detected in these samples and this data was not shown. 
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Figure 59. FOXO3a and CDK5 protein levels in various cell types.  
Western blot analysis of FOXO3a, CDK5 in human adult brain samples from 
controls and Alzheimer’s disease patients, U373 human glioblastoma cell line, 
and human fetal brain. The blot was re-probed with FOXO1 antibody, but no 
signal could be detected. APP, BACE1, and GFAP levels were also assessed 
in these samples.   
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c. Effects of Aβ1-42 challenge on the expression of FOXO1, FOXO3a 
and CDK5 proteins in human neuronal cultures 
Differentiated human fetal neurons (DIV30) were treated with 1 µM Aβ1-
42, 100 µM glutamate, or 100 µM H2O2 for 20 h (Figure 60).  Human primary 
mixed brain cultures (HFB) were prepared and cultured as previously described 
(Ray et. al 2014).  Briefly, cells were cultured in Neurobasal medium (Invitrogen) 
without phenol red supplemented with 1X B27, 50 mM GlutaMAX, 1x antibiotic 
cocktail, 5 ng/mL recombinant fibroblast growth factor 2 (bFGF) (Invitrogen), and 
2 μL/mL Normocin (InVivoGen, San Diego, CA, USA).  Cells were counted and 
seeded onto poly-D-lysine (Sigma-Aldrich) coated 24-well plates (Corning, 
Lowell, MA, USA) at 1.5 x 105 cells per well and maintained at 37°C in a 5% 
CO2 incubator.  Half media changes were performed every fourth day of culture 
and morphology was monitored via IncucyteZOOM.  Culture medium was 
removed from cells on day in vitro (DIV) 30 and replaced with Neurobasal 
medium with B27 minus antioxidant and Aβ1-42, H2O2, or glutamate.  Cells were 
incubated at 37°C for 20 hours.  Cells were harvested after 20 hours.  Cells were 
rinsed with ice cold PBS, then lysed on plate with vigorous shaking using M-PER 
supplemented with 0.1% SDS and protease inhibitor (Roche).  Protein 
concentration was estimated using the BCA Protein Assay (Pierce) per product 
protocol. Cell viability was measured by CTG levels.   
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d. Effect of roscovitine on cell morphology, cell viability of human fetal 
neurons 
Roscovitine (ROSC) is a selective, competitive inhibitor of CDK5 [183].  
We sought to assess the toxicity of this compound in human fetal neurons and 
the effect of treatment on levels of FOXO1 and FOXO3.  Differentiated human 
fetal neurons (day in vitro 30) were treated with 1 µM Aβ1-42, 100 µM glutamate, 
or 100 µM H2O2 for 20 hours.  Human primary mixed brain cultures (HFB) were 
prepared and cultured as previously described (Ray et. al 2014).  Briefly, cells 
were cultured in Neurobasal medium (Invitrogen) without phenol red 
supplemented with 1X B27, 50 mM GlutaMAX, 1x antibiotic cocktail, 5 ng/mL 
recombinant fibroblast growth factor 2 (bFGF) (Invitrogen), and 2 μL/mL 
Normocin (InVivoGen, San Diego, CA, USA).  Cells were counted and seeded 
onto poly-D-lysine (Sigma-Aldrich) coated 24-well plates (Corning, Lowell, MA, 
USA) at 1.5 x 105 cells per well and maintained at 37°C in a 5% CO2 incubator.  
Half media changes were performed every fourth day of culture and morphology 
was monitored via IncucyteZOOM.  Culture medium was removed from cells on 
day in vitro (DIV) 31 and replaced with media with vehicle (2.5% DMSO), 0.1, 
1.0, 10.0, 100.0, or 700.00 µM Roscovitine (Sigma) for 60 hours.   
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Figure 60. Effect of CDK5 inhibitor on cell viability of human fetal 
neurons.  Treatment of HFN with increasing doses of roscovitine showed no 
significant change in cell viability as measured by CTG. % control is viability  
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C. Discussion 
 Of particular interest is the difference in the effect on viability and toxicity 
of MTM and TA when used in combination in a purely neuronal culture.  This 
effect was not observed in the other cell culture systems.  A compensatory 
mechanism involving other members of the SP family may account for the 
divergence in SP1 inhibition between MTM and TA when used separately and in 
combination in neurons.  Use of MTM or the less toxic analog MTM-SDK to 
target SP1 in humans could potentially be a novel drug target in AD.  
Maintenance of synaptic health is a characteristic of interest in a disease 
involving massive neuronal and synaptic loss such as AD.  MTM and MTM-SK 
maintain neurite length and neurite branch points, which could be key in 
preserving synaptic integrity in neurons early in the disease.  Continued use of 
real-time live imaging of cells when treated with these compounds will provide 
increased insight into their effects on the synapse.   
Preliminary data has shown tissue- and cell-specific expression of FOXO 
proteins and the effects of a CDK5 inhibiting drug on human cells.  Future 
experiments should focus on inhibition of CDK5 to degrade FOXO3a as an 
approach to prevent or delay the neurodegeneration associated with AD.  
According to the CTG assay (Figure 60), doses of up to 100 µM of Roscovitine 
are well tolerated in human fetal neurons. Post-translational modifications control 
FOXO protein activity [184].  There could be modifications during the process of 
differentiation leading to activation of FOXO proteins.  CDK5 expression in AD 
brains was decreased compared to controls.  FOXO3a as a substrate of CDK5 
may be differentially activated in AD.  Levels appeared to be decreased in fetal 
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samples as compared to expression levels in adult samples.  FOXO3 expression 
levels seemed to have an inverse relationship with BACE1 levels in these 
samples.   
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VII. Conclusions and future directions 
A. Summary 
Understanding how BACE1 can be regulated by a drug such as an 
antibiotic could lead to innovative therapies for patients suffering from AD.  With 
the LEARn model as the mechanistic framework, discovering a way to regulate 
BACE1 activity in humans could serve as groundbreaking in later onset diseases 
such as AD.  Use of drugs which target regulation of candidate genes at these 
earlier stages of disease will lead to improved bedside approach to patients 
presenting with early symptoms.  Understanding these complex networks of TFs 
and investigating pharmacological strategies to modulate their activity can be a 
novel approach in AD.  We believe that modest, yet specific reduction of BACE1 
via SP1 modulation will provide effective and safe benefit to the brain without 
numerous adverse side effects in combination with existing therapies.  Upon 
completion of this project, we have elucidated a possible mechanism by which 
SP1 regulates BACE1 activity and generation of Aβ in human cells.  A detailed 
understanding of the role SP1 plays in the amyloidogenic pathway in relation to 
the development of AD will have a positive impact by providing a new therapeutic 
target to slow the progression of this devastating disease.   
B.  Other novel approaches to understanding amyloid pathway proteins 
 In addition to understanding the effect of TF modulation of Aβ pathway 
genes, further work should incorporate other novel approaches to targeting 
BACE1 and APP, including miRNAs and trafficking proteins. 
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i. Understanding the effect of miRNAs on the epigenome 
Epigenetic regulation is often described as the alteration of gene 
expression without DNA sequence changes. These mechanisms are associated 
with histone modifications, DNA methylation, and microRNAs.  MicroRNAs target 
transcripts, degrade them, and therefore control the amount of those particular 
proteins [185].  This directly influences the physiological state whether it be 
immediate or after a period of latency.  It has been shown that miRNAs can be 
regulated by epigenetic means such as DNA methylation of their genes just as 
any other protein-coding gene [186, 187].  There are also miRNAs that can target 
DNA methyltransferases (DNMTs) [188].  Hypo- or hyper-methylation of the 
promoter regions of miRNAs can lead to these non-coding small RNAs 
functioning as tumor suppressors or other cancer prone phenotypes [189-191].  
However, changes in mRNA translation due to miRNAs are not truly epigenomic 
because in their case, proteins are the active molecules involved [192].  
Nevertheless, the close connection between the epigenome and miRNome 
means that epigenetically altered miRNAs can lead to pathogenesis that may 
function in a LEARned fashion [193]. The role of environment on the epigenome 
is a major focus on the LEARn model and its explanation of the progression of 
late onset neurodegenerative diseases such as Alzheimer’s disease (AD) and 
other psychiatric disorders [167, 168, 194].  How we interact with the 
environment may indeed affect how miRNAs are expressed and regulated over 
time.  Lifestyle, diet, chemical exposure, and trauma are all environmental 
influences that may lead to epigenetic “hits” that affect the genome in a late
157 
manner.  We know that childhood abuse and adversity can lead to methylation 
changes [195, 196]. Propensity for addiction can be highly influenced by stress 
and other environmental factors [197].  MiRNAs may modulate the cocaine 
response in individuals for which stress has had an epigenetic effect in early-life.  
It has been shown that there is a relationship between miRNA expression and 
reactions to fear and other emotional stimuli [198].  There are miRNAs which are 
induced in anxiety which regulate neurotransmitter pathways and can lead to 
dysregulation [199].  Some of these miRNAs respond to acute stress and may 
even contribute to depressive disorders [200, 201].  Studies have also revealed 
that overexpression of miRNAs is seen in the brains of AD mice, suggesting a 
potential link between these non-coding small RNAs and behavior [202]. It is 
quite possible that changes in DNA methylation caused by these stress or 
anxiety states are passed along through the germline.  There are several 
examples of the LEARn model functioning in a transgenerational manner [80].  It 
is not yet clear how epigenetic changes in miRNA expression can be inherited; it 
has recently been shown that elevated levels of certain miRNAs may be a 
marker for behavioral disorders across generations [203] .   
The case can be made that miRNA function in the same axis of the 
epigenetic process.  Because of their unique biogenesis and mechanism of 
action via mRNA targeting, they cannot be completely categorized as epigenomic 
in nature.  However, because of their unique interaction role in regulation of 
epigenetic processes and their ability to be regulated my epigenetic means, this 
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relationship merits examinations as putative approach to diseases which 
manifest in a latent manner. 
ii. Understanding the role of APP and BACE1 trafficking 
The regulation of APP and BACE1 activity is important in the goal of 
reducing amyloid-beta.  However, understanding how APP and BACE1 
physically interact at the cellular level is key to elucidating alternative strategies 
for changing their prevalence in AD.   
BACE1 is first produced in the endoplasmic reticulum (ER) as a larger 
precursor, pro-BACE1. Pro-BACE1 is subsequently modified by post-
translational glycosylation where the prodomain is removed allowing this protein 
to cross the Golgi apparatus.  BACE1 is then transported to the cell surface 
where BACE1 functions in the regulation of cellular signaling [204]. BACE1 is 
activated through phosphorylation at serine 498 by casein kinase I, and the 
dephosphorylation of this residue leads to endocytosis of BACE1 from the 
plasma membrane. As a result, BACE1 subsequently accumulates in early 
endosomes [205]. Previous studies demonstrate that BACE1 recycles between 
endosomes and the surface of the cell [206, 207]. In order for BACE1 to remain 
in the Golgi where APP processing occurs, a single transmembrane domain is 
required [208]. 
Physical proximity as well as duration plays an important role in the ability 
of enzymes and their substrates to interact with one another, and both factors are 
essential to the processing of APP via BACE1. Therefore, understanding the 
cellular conditions such as protein-protein interactions and cellular signaling 
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which modulate this proximity and subsequent convergence of APP and BACE1 
may provide an important mechanistic key to the regulation of Aβ production. 
Likewise, manipulation of trafficking pathways that decrease the interaction could 
provide a method to inhibit the production of Aβ and possibly provide a cellular 
target to prevent AD pathogenesis or treat the symptoms of AD. 
APP is cleaved by BACE1 to form sAPPβ, the secreted ectodomain and 
CTF99, the C-terminal fragment. Aβ is then liberated from APP is known as 
regulated intramembrane proteolysis (RIP) [209]. Aβ is comprised of a cluster of 
heterogenous peptides of 39-43 amino acids [17].  While the most prevalent 
peptide is Aβ40, the 42-amino acid peptide (Aβ42) has been identified as the 
critical isoform associated with AD. Aβ is typically released in its soluble form into 
the interstitial fluid (ISF) in the brain [21]. However, Aβ aggregates as both 
soluble oligomers and insoluble plaques in AD brain [210]. Pro-BACE1 in the ER 
also displays enzymatic activity that can cleave APP [211]. Consistent with this 
phenomenon, a minority of Aβ42 is generated in the ER, while a greater 
percentage of Aβ42 is observed in the trans-Golgi network [212, 213]. Therefore, 
differences in APP processing by BACE1 in the ER leading to Aβ aggregation 
may provide a key factor in the pathogenesis of AD.  
BACE1 is a transmembrane aspartyl protease with an acidic pH-optimum 
of 4.5 [28]. BACE1 is first localized to the Golgi, and then migrates to the trans-
Golgi network and finally to endosomes. Previous studies indicate that BACE1 
transport may proceed due to several mechanisms. For instance, one study 
found that BACE1 may use an endosomal retrograde transport pathway [214]. 
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Other studies indicate that BACE1 is transported from early endosomes to 
lysosomes [215], and may be recycled from endosomes to the plasma 
membrane [216]. 
The retromer complex is a heteropentameric complex that can be 
separated into two subcomplexes [217]. The trimer component consists of three 
active sites that mediate cargo selection including Vps35, Vps29, and Vps26. 
The dimer component consists of Vps5 and Vps17. In mammals, these 
components are known as members of the sorting nexin family and called SNX1 
or SNX2 and SNX5 or SNX6. Vps35 is the main component of the trimer. Studies 
demonstrate that reductions in Vps35 can lead to retromer malfunction [218]. 
The trimer is responsible for trafficking Vps10 from the vacuole to the 
trans-Golgi. If excessive levels of APP or BACE1 are present, the trimer is 
unable to function properly leading to a buildup of Aβ in the endosome. The 
selective targeting of this cellular mechanism may provide a method that can be 
used to modulate protein trafficking of APP and BACE1, and ultimately Aβ levels.  
In a recent study, the Mecozzi et al. propose that pharmacological chaperones 
can be utilized to manipulate retromer complex stability, thereby affecting how its 
cargo (i.e., APP and BACE) are trafficked throughout the cell. BACE1 and APP 
convergence are critical for the processing of APP. The manner in which APP 
converges with BACE-1 after neuronal activity indicates that neurons have 
developed a distinctive tactic to limit the proximity of APP and BACE-1. Perhaps 
the dysregulation of this mechanism may contribute to increased Aβ production 
and the pathology of AD.   
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iii. Unraveling the LEARn Model 
The link between TFs and AD-relevant processes has been shown.  It 
however, remains unclear the molecular mechanism of drugs that may target 
these TFs and how this can be manipulated at the cellular level.  Accumulation of 
Aβ peptide in the brain remains a key focus of AD pathology.  We postulate that 
non-familial AD is a late onset disease during which early-life exposure (i.e. 
nutrition, experiences, etc.) can lead to epigenetic changes over a period of 
latency that at some later time are triggered to alter phenotypic state.  We 
describe this hypothesis as the latent early life regulation (LEARn) model.  Such 
an early-life exposure that may contribute to this sporadic disease could be the 
environmental toxin lead (Pb).  Pb exposure has been part of recent alarming 
headlines as related to toxic levels in the water of residents of Flint, Michigan in 
the United States.  Pb has long been associated with cognitive decline in humans 
[219].  In rodents, early exposure to Pb resulted in poor performance on cognitive 
tests in aged animals.  [220].  Exposure to Pb in monkeys during development 
leads to an increase in expression of amyloid-precursor protein (APP) and that of 
its rate-limiting cleaving enzyme, BACE1 [221].  The TF known to regulate both 
of these genes, SP1, was also increased in subjects exposed to Pb during 
development.   
In order to test the LEARn hypothesis, experiments using a mouse model 
with human APP, BACE1, PSEN, and MAPT would be ideal for use.  Performing 
standard behavioral tests of these animals would be necessary to establish a 
baseline of epigenetic status.  In a select group of mice, trauma, neglect, 
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exposure to a toxin, or other insult would be introduced at a very young age 
(perhaps during nursing).  Varying periods of time of the exposure and different 
period of time for length of exposure would have to be carefully chosen.  
Behavior would need to be observed over time and compared to the control 
group later in life.  Again, methylation status and histone acetylation activity 
would be measured as well as a battery of behavioral tests.  If in fact mice 
exposed to an early life insult show changes in methylation that correspond to a 
decrease in cognitive function, increase in BACE1 activity, increased plaque and 
tangle production, along with changes in APP, MAPT, and PSEN, this would be 
strong evidence to support the hypothesis that LEARn is a mechanism for the 
development of AD. 
In future studies, we seek to understand the specific regulation of AD-
relevant genes by SP1 and the ability of compounds to modulate SP1 in cultures 
with or without previous exposure to Pb.  Primary human brain cultures and 
induced pluripotent stem cells from controls and AD subjects will be used to test 
the effects of drugs previously shown to decrease Aβ; mithramycin A (MTM) and 
its analogs (MTM-SDK, MTM-SK) at a later time point to observe changes in SP1 
and other TFs, as well as Aβ from neurons exposed to Pb and those without Pb 
treatment.  We wish to understand if Pb is functioning to trigger a period of 
epigenetic latency, and if so, how markers such as histone deacetylase (HDAC), 
DNA methyltransferase activity, and TF levels are affected over time.  Also of 
interest is whether MTM and its analogs can alter these changes when used to 
treat cells after a period of latency.  We expect that early Pb exposure leads to 
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changes in DNA methylation or histone acetylation in neurons that can be 
attenuated via TF-modulating drugs.AD is likely caused by several risk alleles 
across many different loci.  These genes also likely affect several pathways 
involved in the clearance or production of Aβ.  Neuroimaging consists fMRI, PET-
FDG, and other brain imaging techniques to gain structural and functional 
information on biomarkers used for AD classification and early 
diagnosis.  Genome-wide association studies will involve searching for SNPs 
located in genes of TFs that may be important according to AD imaging 
biomarkers.  This work will help to elucidate a possible mechanism for TF 
regulation of AD-related genes via well-characterized compounds in primary 
culture models as well as by candidate SNP searches in the AD Neuroimaging 
(ADNI) database.  The impact of understanding how environmental influences 
such as Pb exposure affect the epigenome of neurons and discovering how 
compounds can potentially reverse these influences is tremendous.  At a time 
when a massive number of US citizens have been highly exposed to toxic levels 
of Pb, it is very important to understand the mechanism by which early life 
changes caused by these tragic exposures may be reversed with available 
compounds such at MTM and its analogs. 
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C. Conclusions 
 The development of new cell culture model systems in neuroscience is 
imperative.  Use of human models in AD study is invaluable as rodent studies are 
not translating into successful clinical trial studies in human subjects.  The human 
fetal neuron culture and the human neurosphere culture both are mixed brain 
models that recapitulate the cellular populations of the CNS.  With this work, 
human dNSPCs, iPSCs, and NBRA cells have been successfully cultured and 
tested with novel drugs.  Testing compounds such as MTM, its analogs, TA, and 
roscovitine in a human system allows a more direct connection to effects that 
may be observed in patients in more advanced stages of study.   
 As use of MTM and TA in humans is extensive and has been well 
documented, we propose repurposing these drugs at nontoxic doses for use in 
AD to reduce amyloid-beta.  Specifically, MTM analogs should be more closely 
examined for their effects on neurobiology and amyloid-beta levels in these 
primary human cultures as they have been here in cell lines.  As MTM-SDK was 
shown to decrease DNMT activity, this may enhance or decrease the ability of 
SP1 to bind to target DNA.  Future studies should focus on how this lesser 
methyltransferase activity directly affects SP1 and other TF binding relevant to 
AD.   
 Broadening our view of TF targeting to include epigenetic modifications as 
well as miRNAs could be novel approaches to neurodegenerative disease 
therapies.  Furthermore, compounds that can alter APP and BACE1 trafficking to 
decrease the proximity of the β-secretase to its substrate may be useful for 
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decreasing amyloid burden.  Lastly, targeting multiple transcription repressors 
and activators such as the FOXO proteins can help us alter AD phenotypes as 
well.  These unique and novel approaches, perhaps if used in combination will 
prove more promising than any of them may be alone.   
Removing amyloid once people have established dementia may be the 
source of failure of prior approaches to AD therapy.  AD may in face be a 
continuum that begins well before any detectable changes in cognition.  Drugging 
TFs that regulate amyloid pathway genes still assumes the amyloid hypothesis is 
correct, however if tolerated could be given much earlier on the AD spectrum 
when early biomarkers become available.  Although TFs have commonly been 
viewed as “un-druggable,” their function as the regulators of gene expression 
make them absolutely necessary in the understanding of the mechanism of novel 
approaches to diseases such as AD that have alluded other solutions for so long.  
It is imperative that these networks continue to be studied and described so that 
treatment strategies can be made available for such a devastating disease.    
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